Podcasts about Neurology

Dr. Aaron Zelikovich talks with Dr. Bhaskar Roy about the latest treatments for myasthenia gravis, comparing their efficacy and safety.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Dr. Aaron Zelikovich talks with Dr. Bhaskar Roy about the latest treatments for myasthenia gravis, comparing their efficacy and safety.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Dr. Jason Crowell and Ka-Ho Wong discuss national trends in Medicare reimbursement for inpatient neurologic care.  Show citation:  Wong KH, Castillo M, King J, et al. National Trends in Medicare Charges and Reimbursement for Inpatient Neurologic Care, 2013-2023. Neurology. 2026;107(6):e218460. doi:10.1212/WNL.0000000000218460 

In this podcast episode, Dr. Brandon Crawford, a chiropractor with training in functional neurology, discusses his work combining functional neurology with photomedicine/photobiomodulation, describing an early pediatric case where laser use appeared to spur unexpected brain development. He explains why some lasers may worsen symptoms (e.g., seizures) due to beam “hot spots,” wavelength energy, and dosing factors such as frequency and duty cycle, emphasizing that light is “information” and not always about increasing ATP. The conversation highlights foundational health strategies—sunlight, grounding, deuterium-depleted water, cold exposure, and reducing screens/non-native EMFs—sharing a case where these improved a child's labs and heavy metal burden. Crawford outlines a developmental functional neurology framework (sensory mapping, primitive reflexes, muscle spindle “conversion,” spinal cord/motor neuron involvement) and discusses PANS/PANDAS as autoimmune encephalitis, focusing on neuroimmune imbalance and individualized treatment that may include targeted activation, nuanced photobiomodulation, and regenerative options like extracellular vesicles, VSEL procedures, and patented Dezawa MUSE cells. He also notes rising neurodegeneration possibly linked to geomagnetic shifts and the South Atlantic Anomaly, and provides ways to contact his clinic and options for telehealth versus intensives.— Connect with Dr Brandonhttps://www.drbrandoncrawford.com/https://www.instagram.com/bcrawforddc/Neurosolution Center of Austinhttps://www.neurosolutionatx.com/https://www.instagram.com/neurosolutionatx/https://www.facebook.com/neurosolutionatx528i Laserhttps://528innovations.com/https://www.instagram.com/528innovations/_________Sponsored By:VIVARAYS  -Go to  https://vivarays.com/sarah and use code SARAH at checkout. Get back in sync with your own rhythm, one sunset at a time._________Timestamp:00:00 Laser Hotspots Problem01:19 Podcast Intro and Disclaimer03:43 Dr Crawford Background08:17 Why Avant Felt Too Much11:11 Light as Information17:02 Foundations Before Detox24:50 Functional Neurology Framework32:29 Geomagnetic Health Concerns34:15 Grounding and Sunlight Tools34:57 Therapy Upgrades TMS PEMF37:43 Screens EMFs and Social Connection42:07 PANS PANDAS Family Journey43:25 Functional Neurology Approach01:02:00 Care Options and Wrap Up——— This video is not medical advice & as a supporter to you and your health journey - I encourage you to monitor your labs and work with a professional!________________________________________Get all my free guides and product recommendations to get started on your journey!https://www.sarahkleinerwellness.com/all-free-resourcesCheck out all my courses to understand how to improve your mitochondrial health & experience long lasting health! (Use code PODCAST to save 10%) -  https://www.sarahkleinerwellness.com/coursesMy free product guide with all product recommendations and discount codes:https://www.canva.com/design/DAF7mlgZpJI/xVyE4tiQFEWJmh_Xwx8Kbw/view?utm_content=DAF7mlgZpJIFree Webinar on Light & Health (includes free light bulb guide) - https://www.sarahkleinerwellness.com/mycircadianapp-free-webinarGet Early Access to Podcast Episodes & my Seasonal Food Course + UVB+Red Light Therapy course for free -  https://open.substack.com/pub/sarahkleinerwellness/p/uvbred-light-protocol?r=5eztl9&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true

The September 2026 Recall features four previously posted episodes highlighting updates in child neurology. The episode begins with Dr. Andrew Hershey discussing advances in the treatment of pediatric migraines. Next, Dr. Serena Orr discusses the genetic risk of migraine and post-traumatic headache in children. In the third episode, Dr. Coral Stredny reviews the management of pediatric convulsive status epilepticus, with a focus on seizure action plans and adherence to treatment protocols. The episode concludes with Dr. Scott Perry discussing approaches to improving the transition from pediatric to adult epilepsy care.  Podcast links:   Fremanezumab in Children and Adolescents with Episodic Migraine  Post-Traumatic Headache in Children and Genetic Risk of Migraine Seizure Action Plans in Pediatric Convulsive Status Epilepticus  Navigating the Transition From Pediatric to Adult Epilepsy Care   Article links:  Fremanezumab in Children and Adolescents with Episodic Migraine  Post-Traumatic Headache in Children and Genetic Risk of Migraine Assessment of Seizure Action Plans in Pediatric Convulsive Status Epilepticus  Addressing Barriers to Transitioning Pediatric Patients With Epilepsy to Adult Health Care in the United States Disclosures can be found at Neurology.org. 

Insomnia affects neurologic health, quality of life, and daily functioning, but effective treatments are available. In this episode, Dr. Brandon Peters-Mathews discusses a practical approach to evaluating chronic insomnia, highlights the importance of identifying contributing conditions such as sleep apnea and mood disorders, and reviews cognitive behavioral therapy for insomnia (CBT-I), the recommended first-line treatment. Learn how addressing sleep can improve outcomes across a wide range of neurologic disorders. In this episode, Katie Grouse, MD, FAAN, speaks with Brandon R. Peters-Mathews, MD, FAAN, FAASM, author of the article "Insomnia" in the Continuum® August 2026 Sleep Neurology issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California, San Francisco in San Francisco, California. Dr. Peters-Mathews is the Section Head of Sleep Medicine at Virginia Mason Franciscan Health in Seattle, Washington. Additional Resources Read the article: Insomnia Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @BrandonPetersMD Full episode transcript available here Dr Grouse: Insomnia may be one of the most common medical issues experienced by patients, yet our knowledge about how to manage it remains limited. Today, I have the opportunity to speak with one of the world's leading experts on sleep disorders, Dr. Brandon Peters-Mathews, about the latest issue of Continuum on Neurology of Sleep.  Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Grouse: This is Dr. Katie Grouse. Today, I'm interviewing Dr. Brandon Peters-Mathews about his article on insomnia. This article appears in the August 2026 Continuum issue on Neurology of Sleep. Welcome to the podcast, and please introduce yourself to our audience.  Dr Peters-Mathews: It's my pleasure to join you, and I'm happy to talk about this article. I think it's an interesting one for most folks. I am a board-certified sleep neurologist. I practice at Virginia Mason Franciscan Health in Seattle. I did my neurology training back at the University of Minnesota and my sleep training at Stanford University. I've been in practice for more than thirteen years at this point. It's hard to believe, but it's exciting to be able to speak with you today.  Dr Grouse: This is definitely an important topic for everybody. Certainly, sleep and the lack of it affects all of our patients, and I can't imagine there's a single clinical neurologist who doesn't have to answer questions and help evaluate patients with this problem, so very high-yield topic for everyone. Now, having read your article, I'm curious if you had to choose one key point that you want the readers of your article to take away after reading it, what would it be?  Dr Peters-Mathews: Emphasize for my patients that insomnia is a condition that we can work through and resolve, that if we really can understand the underlying contributing causes and resolve those issues, we can typically improve sleep. It's a process. It takes time. It takes some attention and, and sometimes even testing to figure out what's going on. But if we can dial into these root causes, we can typically help somebody to sleep much better. As part of that, we often employ a therapy called CBT-I, which we'll talk about here a little bit later. But that also helps us to identify some of these contributing factors that are leading to the poor sleep.  Dr Grouse: And I definitely want to talk more about CBT, it's such an important topic. But even before we get into that, I'd love it if you could just walk us through a hypothetical case of a patient with insomnia. I think the type of patient that I think we've all seen in our clinical practice and somebody who says, "You know, I've had poor sleep. I've had insomnia for many years. I've tried all of the things you're supposed to try. You know, I've tried sleep hygiene. I've tried this. I've tried that. I've tried medications. Nothing seems to work." Could you walk us through how you would evaluate a patient like this and start to consider what to recommend? Dr Peters-Mathews: So, some simple information that we can gather, would be information about when they're trying to go to bed, how long it's taking them to fall asleep initially. If they wake in the night and have trouble getting back to sleep, how often they wake in the night. If they're experiencing early morning awakenings, their final wake time, and when they actually get out of bed in the morning. That gives me a sense of the structure of their sleep pattern and whether or not they might be spending an excessive amount of time in bed for their own sleep need at their current age. The other factors that we might consider are sleep disorders, and typically, I would assess for other symptoms that would point me towards sleep apnea or restless legs and occasionally other disorders of sleep. We wanna make sure we're not missing comorbid conditions that might be affecting that person. These often include mood disorders. Sleep and mood walk hand in hand, and so anxiety and depression are important to identify and treat if present. We also want to make sure someone's not suffering from chronic pain or other conditions that might be impacting their sleep. So, I take a broad approach. I ask the same questions to each patient that comes to see me. I wanna make sure I'm not missing some of these details. And then some of these folks will require testing to further understand their sleep. Others may move on to a different therapy, and long-term may require even other interventions, including medications, to fully resolve their condition.  Dr Grouse: You mentioned in your article circadian rhythm sleep disorders. How often are these really a factor in patients with chronic insomnia? And do you think that's something that we as kind of first-line clinicians should be screening for as well?  Dr Peters-Mathews: So delayed sleep phase syndrome is the most common circadian disorder, and these are folks who are night owls by nature. They often develop their sleep patterns, as teenagers, if not before, and they may fade away in the working years but come back in retirement age. I would say that's a very common condition. It may affect as many as one in ten people. The other circadian disorders are pretty uncommon, so advanced sleep phase syndrome, where somebody is sleepy early and waking too early, that may only affect one in three hundred people. There are other conditions that affect specific populations, like non-twenty-four circadian pattern affects blind people. Typically, half of blind people have that condition. There are conditions that affect the regularity of sleep, so an irregular sleep-wake pattern that might occur more in folks with maybe an advanced dementia. So, there are populations where these conditions can be fairly common, but among the general population, that night owl tendency is by far the most common.  Dr Grouse: That's really helpful. And just taking a step back, why is insomnia bad for us? So, we worry about this in our patients. We know it can make neurologic issues worse. But in general, like, what are the reasons that having poor sleep can affect our health? Dr Peters-Mathews: Yeah, and it's not enough hours, certainly quantity, but also quality of sleep that matters. And I tell people that sleep is a pillar of health, just like nutrition and exercise. It's the other main contributor to our health and well-being. And so, it has its fingers in almost every aspect of our health. Insomnia on its own is a risk factor for other psychiatric conditions, including depression, anxiety, even disorders like bipolar and schizophrenia. Folks with insomnia are more likely to have alcohol or drug abuse issues and are at higher risk for things like chronic pain, suicide and, and social and occupational dysfunction. So, it's a disorder that has a really profound effect on how someone functions during the day, and again, may take a toll on their health over time.  Dr Grouse: That makes sense, and I would assume that there are certain populations within our neurology practices where we should really be attuned to the risk of insomnia. Are there specific populations you'd recommend really make it a habit of screening for insomnia?  Dr Peters-Mathews: I was joking with someone recently that anyone with a neurological nervous system can have issues, impacted by poor sleep. There are certain groups, so chronic headache patients are perhaps one that might warrant a further evaluation and management. Folks with multiple sclerosis or Parkinson's may have physical conditions that lead to more discomfort in sleep, fewer movements of their body in sleep, issues around nocturia that would disturb their sleep. Certainly, those with dementia, Alzheimer's disease and other dementias. Parkinson's and Lewy body dementia overlap a lot, as does multiple system atrophy. That can point us towards other conditions like REM sleep behavior disorder, but also insomnia can be an important feature of those disorders as well. And then folks with stroke often have disturbance to their sleep and may develop insomnia after experiencing a stroke. So those are specific populations where I think the yield is high to be looking for insomnia and other sleep disorders.  Dr Grouse: Yeah, that makes sense. I think a lot of us think of insomnia as almost like, make sure we're not missing this as sort of a mimic of the problem, when in fact it's probably just more part and parcel of the problem and something we need to be thinking about treating as part of their disorder. So helpful to think about it in that light, at least in my own mind. Now, I want to get a little bit back to some of the therapies you've recommended, and I think first just stopping again at sleep hygiene. Your article has a really great list, I think, of sort of like a checklist of actions that people should be taking to make sure that they are managing their sleep hygiene well. And I definitely recommend our listeners look to that. How often do you think that focusing on sleep hygiene helps when you get a patient who says, "Hey, I have got terrible sleep. You know, what do I do?"  Dr Peters-Mathews: It's pretty common for people to have access to this information through their own reading online, and most folks have worked through this by the time they've come to see me, and often a primary care provider or specialist may have given some of this guidance as well. It's pretty rare for them to not recognize something as obvious as having caffeine too late in the day by the time they're coming to my attention. The sleep hygiene generally is used as a control when we do research to look at how something like medication is working or CBT-I might be working. It's the comparative control. It's almost like the null intervention. So, it's not highly effective, and if folks are not finding it helpful, they've made those adjustments to their sleep environment or their habits, and they're continuing to have issues, there's typically more that needs to be done, and that's where CBT-I really comes in as a strong intervention for those people.  Dr Grouse: And then getting on the topic of CBT-I, so helpful. I'm really glad that your article spent a lot of time talking about it as really a truly high-yield, great intervention for insomnia. And I really felt that the question shouldn't be: When is cognitive behavior therapy for insomnia helpful? But like, when isn't it helpful? What are your thoughts about that?  Dr Peters-Mathews: Yeah. I always point out that the American College of Physicians has recommended CBT-I for adult patients as the initial treatment for chronic insomnia even before the use of a medication for nearly ten years. That recommendation came out in July of 2016. So, there are folks who may not be good candidates for it, who may be screened out because of other conditions that they have, and there certainly are folks who don't do as well with CBT-I. And adherence is important. Somebody needs to be able to follow the instructions and apply that to their lives. And certainly, there are a number of things that could interfere with that compliance. I would say untreated anxiety and pain are two things that often trip people up. It's like running a race with a broken leg. Despite their best efforts, if those are not addressed, they will continue to have issues around insomnia. And then one thing that often is unrecognized and may be missed is untreated sleep apnea. That is a common contributor to a chronic insomnia, especially in older folks, women beyond the age of menopause and men even starting in middle age, thirties and forties. We don't want to miss sleep apnea. Even insomnia that's, "I can't fall asleep at the beginning of night," that could still be sleep apnea, so that's something I really emphasize with my patients.  Dr Grouse: Really great reminder about sleep apnea for sure. Something that always is beneficial to make sure we are not missing. Oftentimes I'll bring up a CBT for insomnia, and what is that? Like, what would we actually do, and what is a high-level overview of what happens with CBT-I?  Dr Peters-Mathews: Yeah. So, I generally tell my patients that this is a six-week program. It's a structured program, almost like a boot camp for sleep, in which we are addressing underlying causes, recognizing what those are and, and working through those underlying causes. There is often tracking using a sleep log or sometimes wearable data.To guide decisions that are made in the program. It's very goal-directed, science-based therapy. We often introduce concepts around sleep drive, circadian rhythm dealing with a busy mind at night. There's concepts of mindfulness and relaxation training that are introduced. People often are able to taper or stop using sleeping pills as part of this therapy. And the nice thing is they walk away with a set of skills that they can apply the rest of their lives to sleep more normally. And so, there's good research that suggests even years after someone's completed a CBT-I course, they continue to sleep more normally. They have the tools that they need to sleep better even years beyond that education.  Dr Grouse: You know, this just sounds so great. It almost sounds like why wouldn't someone benefit from this? But of course, like I would imagine many institutions experience, I've definitely run into difficulties with access for my patients for CBT-I, and we have long wait lists. And I imagine there's many places where there just aren't even any specialists that patients can get to, to help with this. What are the resources that our listeners can take advantage of for their patients to get access to these types of therapies?  Dr Peters-Mathews: So, one thing I tried to really emphasize in the article is that there are resources that can be drawn in. I'll give you some examples. So, at our institution, we have three sleep specialists, full-time sleep specialists, who trained at Stanford to become CBT-I specialists, and so we have more resources than probably most institutions would have. We do shared medical appointment workshops so that we can manage the number of patients that we have to see. And, and unfortunately, not everybody has that opportunity. You might plug into resources in your community, and one of the resources I point to in the article is the International Directory that's managed by the University of Pennsylvania that has eight hundred and seventy-five CBT-I specialists listed with contact information, et cetera. And I think that's an amazing opportunity to access this therapy. Unfortunately, there are countries and certainly states that do not have a specialist, that there's no one in the state that provides this therapy. And then we need to extend other resources, and that could be online treatment programs that can be done independently, bibliotherapy, so accessing books that could guide people through the therapy, even accessing other apps and maybe even wearables that pair with an app that could provide some of this guidance. The Veterans Administration worked with Stanford and worked with the National Center for PTSD and developed an app called CBT-I Coach that is free and can be downloaded and, and gives, I think, good education, good guidance. So, there are resources that exist. It's somewhat finding what might work for your individual patient, how they're preferring to access this or their learning preferences. Do they want to read a book or not? And getting them into the right pathway.  Dr Grouse: And I think that gets me into a whole other Pandora's box of the fact that they're already out there in the world are tons of different apps, wearable devices, all sorts of things that promise that they can help us with sleep, some that may have more, I think, data and evidence behind them than others. Do any of these apps or wearables in your mind show promise in our patients helping our patients track and diagnose and manage their insomnia?  Dr Peters-Mathews: Yeah, there's a lot out there, and unfortunately, some of these devices actually can make sleep worse. People can develop a condition called orthosomnia or straight sleep, where they're trying to perfect their sleep and their sleep numbers, their metrics, and the wearables feeding them data that they continue to try to improve upon. And that fixation on those metrics can actually make their sleep quite a bit worse. A lot of these wearables and apps and other resources have not been well-studied. There's not research trials showing outcomes comparing to other standards of care. I would say the basic guidance of CBT-I, which many of these programs are based on, I think will be helpful to the majority of folks who are able to engage and complete that education. A lot of these are not dependent on that sort of framework or structure so that we may not actually be using the standards of CBT-I to try to improve sleep. They may be connecting you with other resources, like listen to this sleep story or this relaxation file or do some meditation, et cetera, which again, may be of some benefit, but it is not the same as a structured CBT-I experience. So, I think there are a few good resources that we highlight within the article, and I think there are probably others coming that may give individuals a more individualized, directed approach to managing their sleep issues. But it's almost like going to the App Store and there's thousands of apps. It's hard to know which one might be most based on science or the most beneficial to that individual.  Dr Grouse: Well, I really appreciate in your article that you did have a great list of apps and things along those lines to try, so I do encourage our listeners to check that out as well. Some really, really great resources there in the article in many different areas. Now, I wanted to turn the conversation to a slightly different thing, which is medications for insomnia. Now, when are medications appropriate for treating insomnia? When should we be thinking about turning to these for our patients?  Dr Peters-Mathews: So again, we would suggest that CBT-I would be first, and that failing improvement with CBT-I, that medications would be extended to a person affected by insomnia. And over-the-counter options as well as prescription medications might be used. Unfortunately, that's not how things unfold in the real world. Many people are jumping to medications first, whether that be an over-the-counter supplement or other medication, or they're seeing primary care and other specialists who's providing them a prescription for sleep aid. So there's data from the CDC going back to twenty twenty that suggests that about six point three percent of adults were taking a sleeping medication every day in the months prior to the survey. And women who were older than sixty five, white women, were more likely to be using a sleeping medication every day. That number was 13.5 percent of those surveyed. So, lots of folks are on medications, and certainly melatonin is widely used. Unfortunately, it's not regulated by the FDA in a sense that we don't have exact concentrations controlled. So, people can take melatonin that has no melatonin in it. They might take melatonin that's forty or more times the dose. There's variance within lots from the same manufacturer. There's a lot of trouble knowing exactly what you're getting when you try to take something like melatonin over the counter. Other sleep aids that we might reach to over the counter, like variants of diphenhydramine or doxylamine, and these are often the PM drugs that we think about. They have risks associated with population-based studies which suggest risk of dementia, risk of falling, risk of mortality with these drugs, especially in older populations. So again, that would give us potentially pause. The prescription medications that we go to, there are some that the American Academy of Sleep Medicine would recommend as more beneficial than harmful, and some are good for both initiating and maintaining sleep. Some have such a short half-life that they're really best as initiation drugs. And then others are better for maintenance of sleep, so reducing awakenings and wakefulness in the night. My own individual take, often people are coming to me on medications, typically over the counter, but often prescriptions, and have even tried and failed many of those medications before they finally come to see a specialist. And so, I don't often reach to medications until I've exhausted CBT-I, until we've completed a sleep test to make sure we're not missing something like sleep apnea, until we've ruled out some other potential contributing causes. But there are patients I have who really will not sleep without medication support and sometimes even multiple medications that work in complementary ways to try to normalize their sleep. And so, in some cases it is necessary, but it is not meant to be a first line for anyone.  Dr Grouse: Yeah, and I think all of our listeners can relate to the fact that we often see patients who've been on sleep medicines for many, many years and take them every night. It's good to know that there is sort of a procedure here to consider and perhaps again, back to the plug to CBT-I as being the right starting point to see if there's some that we can help get off of these meds, although, as you mentioned, maybe not always going to be successful. Well, I really appreciate our conversation about this. It's been really great to read this article about insomnia. Again, I encourage our listeners to check it out. Some really great resources for many different therapies, thinking about other alternative diagnoses and different medical conditions where insomnia really needs to be considered. And I really appreciate you writing this article. It's been a pleasure to talk with you today.  Dr Peters-Mathews: It's my pleasure to share this information with folks, and I hope that you find it useful in your clinical practice or even your personal life as the need arises.  Dr Grouse: Again today, I've been interviewing Dr. Brandon Peters-Mathews about his article on insomnia. This article appears in the August 2026 Continuum issue on Neurology of Sleep. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audiocme. Thank you for listening to Continuum Audio. 

My guest today on the Online for Authors podcast is Sean Pauzauskie, author of the book Stage of Fools. Sean Pauzauskie, M.D., is a hospital neurologist in the University of Colorado system, where he conducts clinical research employing neurotechnology, primarily for the optimization of epilepsy management. He is an active member of the American Academy of Neurology and The American Medical Association, and his research experience includes time at The National Institute of Mental Health, The Energy and Commerce Committee of the U.S. House of Representatives, and the Kaufmann Foundation for entrepreneurship. He is also a member of the American Academy of Neurology's Palatucci Advocacy Leadership Forum, a highly competitive program that selects 30 out of 40,000 members to develop and implement action plans on advocacy issues related to neuroscience. He is president-elect of the Colorado Medical Society.   As a clinician who works daily with comatose patients, Sean brings scientific authenticity to his literary exploration of cognitive-motor dissociation—a condition where patients remain mentally aware while physically unresponsive.   In my book review, I stated Stage of Fools is a literary fiction by Sean Pauzauskie. We quickly meet Thomas Mariner, a billionaire who appears to have it all - until an unfortunate fishing accident leaves him in a coma in a San Francisco ICU.   The entire story is in the mind of Thomas while he is in a coma and flashbacks to his childhood and early adulthood. Despite his fortune and fame, Thomas has demons, and these demons have created problems in his family. His hope? To figure things out, make the needed changes, and save them from what he set in motion due to jealousy, his ego, and rash actions.   I think what is most interesting is that the author is a neurologist. He offers a lot of information to help us understand what it might be like inside a brain during a coma. And for Thomas, his obsession with the play, King Lear, shows up throughout.   I found the novel interesting and thought-provoking with an ending I didn't expect.     Subscribe to Online for Authors to learn about more great books! https://www.youtube.com/@onlineforauthors?sub_confirmation=1   You can follow Author Sean Pauzauskie Website: https://seanpauzauskie.com/ Social media: IG: @seanpauzauskie LinkedIn: @sean-pauzauskie FB: @sean.pauzauskie   Purchase Stage of Fools on Amazon: Paperback: Hardback: https://amzn.to/4pcLB3A Ebook: https://amzn.to/44WBcQe   Teri M Brown, Author and Podcast Host: https://www.terimbrown.com FB: @TeriMBrownAuthor IG: @terimbrown_author X: @terimbrown1   Want to be a guest on Online for Authors? Send Teri M Brown a message on PodMatch, here: https://www.podmatch.com/member/onlineforauthors   #seanpauzauskie #stageoffools #literaryfiction #terimbrownauthor #authorpodcast #onlineforauthors #characterdriven #researchjunkie #awardwinningauthor #podcasthost #podcast #readerpodcast #bookpodcast #writerpodcast #author #books #goodreads #bookclub #fiction #writer #bookreview *As an Amazon Associate I earn from qualifying purchases.

Dr. Jason Crowell talks with Ka-Ho Wong about national trends in Medicare reimbursement for inpatient neurologic care, including the widening gap between hospital charges and payments and its implications for healthcare policy.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Multiomics: The Next Frontier In Precision Medicine And Diagnostics Standard blood tests aren't giving you the most accurate picture of your health. Our expert examines the critical blind spots in standard medical testing and reveals emerging technology that catches disease at the cellular level. Guest: Dr. Adrijana Kekic, CEO & founder, Futurome Host and Producer: Kristen Farrah   Closing The Info Gap: A New App That's Empowering Patients And Caregivers Patients routinely forget up to 80 percent of the information shared during a doctor's appointment. Thankfully, a new app puts control directly back into the hands of patients by bridging this critical information gap and eliminating the stress of lost instructions. Our expert explores how empowering individuals with clear, accessible records of their care can transform the patient experience and relieve burnout for healthcare providers. Guests: Dr. Arpan Parikh, psychiatrist, CEO & co-founder, Kin Health Host: Greg Johnson Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Multiomics: The Next Frontier In Precision Medicine And Diagnostics Standard blood tests aren't giving you the most accurate picture of your health. Our expert examines the critical blind spots in standard medical testing and reveals emerging technology that catches disease at the cellular level. Guest: Dr. Adrijana Kekic, CEO & founder, Futurome Host and Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why do we crave some foods the more often we eat them? Are we addicted?Dr. Dana Small's research suggests that food craving reaches far beyond taste or willpower, and that “addiction” isn't a helpful descriptor. Every time we eat, unconscious signals from the body teach the brain which foods deliver useful nutrients, and train us to want more of those. In other words, we don't eat crave foods because they taste good; foods taste good because our body craves them.Understanding that means we can rethink overeating. It's not a matter of addiction or self-control; it's our body behaving the way nature intended it to, but in the setting of foods not found in the wild, like those high in both fat and carbohydrates. But we may also be able to train our brain away from these cravings.Free course: Improve your metabolic healthGet our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠What We CoverTaste vs. flavor, pleasure, motivation, and food rewardHow gut nutrient signals teach the brain which foods to seekWhy fat + carbs produce an unusually strong reward responseWhat eight weeks of high-fat, high-sugar snacks did to the brainHow GLP-1s may cut food wanting while preserving pleasure

In part two of this series on the 2026 Alzheimer Association International Conference, Dr. Greg Cooper talks with Drs. Trey Bateman and Gregg Day about recent clinical trials, evolving treatment strategies, and prevention efforts.    Disclosures can be found at Neurology.org. 

In this episode, I speak with my producer, Tony, to answer questions from the listeners and we discuss: The neurology of depression Rumination, inhibition and the frontal cortex The underrated benefits of strength training Motivation and making small changes Does stretching actually work? Stretching for pain vs performance Fixing a sensitive nervous system Bottoms up vs top down clients Building resilience The fuel problem Balancing assessment with training And more... Thank you to my podcast idea man and coach, Tony Fowler (Instagram: @tone_reverie) for helping me put together this episode! Free Resources: Join our mailing list HERE to stay up to date on the latest updates from Kruse Elite Join our free Cranial Nerve Masterclass here to get a taste of how neurology impacts your movement and pain issues Subscribe to our YouTube HERE for in-depth educational videos and tutorials Whenever you're ready here's how we can help you: Become an expert in problem solving movement and pain issues with our beginner neuro course, Neuro Foundations Master applied neurology so you can feel confident you can help anyone who walks through your door by joining our advanced neuro course, The Neuro Dojo

Dr. Justin Abbatemarco recaps a presentation on Hashimoto encephalopathy from the AAN Autoimmune Neurology Conference.   Show citation:    Valencia-Sanchez C, Pittock SJ, Mead-Harvey C, et al. Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Commun. 2021;3(2):fcaa233. Published 2021 Jan 5. doi:10.1093/braincomms/fcaa233    Brain, Jellinek E, Ball K HASHIMOTO'S DISEASE AND ENCEPHALOPATHY The Lancet, 288, 512-514    Mattozzi S, Sabater L, Escudero D, et al. Hashimoto encephalopathy in the 21st century. Neurology. 2020;94(2):e217-e224. doi:10.1212/WNL.0000000000008785

Central sleep apnea is a complex and often underrecognized sleep-related breathing disorder that differs from obstructive sleep apnea by involving reduced respiratory drive rather than upper airway obstruction. In this episode, Dr. Ran Liu reviews the underlying mechanisms of central sleep apnea, including the role of ventilatory control instability, discusses its association with neurologic conditions such as stroke, multiple sclerosis, ALS, and myasthenic disorders, and highlights key considerations for diagnosis and management. Learn how emerging technologies, personalized treatment strategies, and advances in sleep medicine are improving outcomes for patients with this heterogeneous group of disorders. In this episode, Teshamae Monteith, MD, FAAN, speaks with Ran R. Liu, MD, FRCPC, MSc, author of the article "Central Sleep Apnea" in the Continuum® August 2026 Sleep Neurology issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Liu is an Adjunct Clinical Assistant Professor at McMaster University in Hamilton, Canada, and an Adjunct Lecturer at the University of Toronto in Toronto, Canada. Additional Resources Read the article: Central Sleep Apnea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @SleepyNeuroDoc  Full episode transcript available here Dr Monteith: You may be familiar with obstructive sleep apnea, but central sleep apnea is often less understood and frequently underdiagnosed. In this podcast, we break down the key clinical pearls to sharpen your diagnostic reasoning, discuss why central sleep apnea matters, and to explore some of the fascinating advances transforming the field. Dr Jones: This is Dr. Lyell Jones, editor-in-chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Monteith: This is Dr. Teshamae Monteith. Today, I'm interviewing Dr. Richard Liu about his article on central sleep apnea. This article appears in the August 2026 Continuum issue on Neurology of Sleep. Welcome to our podcast. How are you?  Dr Liu: Good. Thank you, Dr. Monteith, for having me today.  Dr Monteith: Please introduce yourself to our audience.  Dr Liu: Hello, everybody. My name is Richard Liu. I am a sleep neurologist. I am working out of Toronto at both Sunnybrook Health Science Center and MedSleep. I did my residency at Queen's for neurology and my sleep medicine fellowship at Harvard University.  Dr Monteith: Great. And what got you interested in sleep?  Dr Liu: Thank you very much for asking. For me, sleep medicine is a field where essentially everything is connected. Certainly, impaired sleep can affect many other conditions, including many neurological conditions. And even within sleep medicine, when somebody has a sleep disorder, often the entire system is connected. So as an example, if you have insomnia and fragmented sleep and periodic limb movements of sleep, certainly these conditions can impact sleep apnea. And certainly, for today's topic of central sleep apnea, this is an extremely complicated disorder where it's a very in-depth integration between neurological and respiratory physiology, among other systems as well.  Dr Monteith: So, I guess you're kind of like the cornerstone, sleep being the cornerstone of neurology. Everyone has to sleep. That's for sure. Great. So why don't we talk about what central sleep apnea is, and how prevalent is it as a collective group of disorders compared to obstructive sleep apnea?  Dr Liu: So, one way to think about central sleep apnea is that this is a heterogeneous group of etiology. But the primary concept here for central sleep apnea is that there's a reduction in respiratory drive. This is in contrast to obstructive sleep apnea, where essentially this is some form of airway obstruction in the presence of relatively intact respiratory drive. And of course, there's mixed apneas where they may contain features of both. But of course, now we know that even obstructive sleep apnea, there's a certain degree of drive dependence somewhat blurring these distinctions. The overall prevalence of central sleep apnea is about five to ten percent of all patients with sleep- disorder breathing. And certainly, it could be higher in some neurological conditions, such as things like stroke, multiple sclerosis, and multisystem atrophy.  Dr Monteith: Great. So certainly, it's out there. Why don't you tell us about the objectives of your article?  Dr Liu: Absolutely. Thank you for asking. I think the main objective of this article is really to highlight that central sleep apnea is a complex syndrome resulting from a large group of heterogeneous etiologies. And of course, again, it could be associated with many neurological conditions. And really here, I want to highlight advancements, both medicine and technology, on both the side of diagnosis of central sleep apnea, as well as the multimodal targeted treatment.  Dr Monteith: And what do you want our listeners to take away from this talk and certainly your article? What are the key essential points?  Dr Liu: Thank you very much for asking. I think that one way of looking at central sleep apnea to etiologically divide this into both hypocapnic and hypercapnic central sleep apnea. And of course, loop gain being a major driver for a hypocapnic central sleep apnea, and that one can actually think about hypocapnic central sleep apnea beyond a phenotypic spectrum with obstructive sleep apnea, with many patients having overlapping features of both obstruction and central component. On the other hand, hypercapnic central sleep apnea, often also known as hyperventilation syndrome, can span etiology from chemoreflex dysfunction to a broad range of neuroanatomical localization, such as central nervous system, peripheral nervous system, neuromuscular junction, and muscle disorders.  Dr Monteith: And what are some of the symptoms of central sleep apnea? Do any of them differ from obstructive sleep apnea?  Dr Liu: Thank you for asking, that's an excellent question. So certainly, central sleep apnea symptoms can overlap with obstructive sleep apnea symptoms. And of course, given the large range of underlying etiology, often the CSA symptoms depend on the underlying etiology. There may be less snoring compared to obstructive sleep apnea patients, especially the hypocapnic CSA patients. Of course, these patients, like OSA, may have frequent awakenings, gasping and choking their sleep, and nocturia, and so on.These patients may have daytime sleepiness, insomnia-like symptoms, or they could be asymptomatic. Interestingly, the hypocarbnic central sleep apnea patients, they're a bit more prone to have the insomnia-like symptoms, whereas the hypercarbnic central sleep apnea patients, they tend to have a bit more of the daytime sleepiness and morning headaches.  Dr Monteith: You spoke about some of the neurological disorders that might be associated with central sleep apnea, like stroke and multiple sclerosis. What about some of the more traditional risk factors associated with obstructive sleep apnea or conditions associated with it, like obesity and hypertension? Or does that just mix the picture?  Dr Liu: There is many overlap between risk factors between obstructive sleep apnea and central sleep apnea, and certainly one of the things that I highlight in this article is really that often it's not just black and white, that this could be a spectrum with overlapping disease between both conditions. So certainly, in our neurological world, stroke is the most common thing that may be associated with central sleep apnea. But overall, cardiovascular issues such as heart failure, atrial fibrillation, these things can also be associated with central sleep apnea. And again, from the neurological perspective, if we were to divide from hypocarbnic versus hypercarbnic central sleep apnea, by thinking about the hypercarbic central sleep apnea, again, this is where we're thinking about hypoventilation syndromes. You know, anything that can cause neuromuscular weakness, this is something that we should have a high alarm for, that potentially there may be a hypoventilation component. So, things like any myasthenic syndromes and ALS.  Dr Monteith: Great. Why don't we also talk about the classification? When was the last time central sleep apnea's classification was updated, and what should we know about the classification?  Dr Liu: The most recent classification for central sleep apnea is written in the International Classification of Sleep Disorders, third edition. In this edition, it's classified with six central sleep apnea syndromes. So, these are the CSA with Cheyne-Stoke breathing, CSA due to high altitude periodic breathing, primary CSA, CSA due to medication or substance, CSA due to medical disorder without Cheyne-Stoke breathing, and treatment-emergent central sleep apnea. These classifications more so describe the circumstance of when CSA occurs. A more etiological classification that we can consider would be classifying them by the underlying pathophysiology, which is dividing this from hypercarbnic central sleep apnea versus a hypocarbnic central sleep apnea. Certainly, both set of classification are discussed in this article.  Dr Monteith: Yeah. You discussed at length, the major physiological factors that our audience is just going to have to read. I don't want them to hear this too much while they're driving or on the treadmill, cause its super high level. But why don't we just start with some very basic factors that we need to know about this circuitry?  Dr Liu: Perhaps I can start with this concept of loop gain, which is the most important concept under hypocarbnic central sleep apnea. For any one of my colleagues who's listening to this, they're probably laughing right now cause they think that loop gain is my favorite word. So, loop gain is an engineering term referring to the sensitivity of a feedback loop. So, in the context of sleep medicine, this is an overly sensitive respiratory control to carbon dioxide and oxygen fluctuation. There are three components. The main one is controller gain. This is a chemosensitivity predominant to CO2. The second is plant gain, which is the lung's effectiveness for carbon dioxide excretion. And the last is what's called the mixing gain. This is circuitry delay from the time the signal travels from the pulmonary artery to the peripheral and central chemoreceptors. So conceptually, one may think, let's say something decreases your ventilation, so for example, apnea or hypopnea. With this, as you can imagine, when you stop breathing, your CO2 builds up, and this builds up according to the curve of the plant gain. And of course, this build of CO2 signal takes time to go from your lung to your chemoreceptor. That's your mixing gain. And of course, here it meets the overly sensitive chemoreceptors. This is your controller gain. As a result, this results in amplification of your ventilation to the initial respiratory disturbance. So, you have a overshoot of ventilation. All of a sudden, you're blowing out too much carbon dioxide, then you become hypocarbnic. At one point, if you blow out way too much carbon dioxide, your CO2 goes below what's called a PCO2 apneic threshold. After this, if your CO2's below, you essentially stop breathing. And of course, after that, you can imagine your CO2s are building up again. So, when this loop goes over and over, you generate what's called a chemoreflex-driven respiratory oscillation, where you create a crescendo, decrescendo-like flow pattern, which is underneath what we see in periodic breathing in central sleep apnea.  Dr Monteith: So, without going into too much detail, what is the key way to target restoration of equilibrium? Are there anatomical targets, physiologic targets that we're trying to manipulate here? Dr Liu: Again, thank you very much for that wonderful question. There's certainly many approaches that we could do to improve the stability of the system. Certainly, there are treatments for ventilation, either CPAP or in the case of hypocarbon central sleep apnea, things like adaptive servo ventilation. There is also medications that we can certainly discuss later that can double down the entire system for loop gain. Positional therapy can help for many of these patients. For the appropriate patient, improving their arousal threshold can actually reduce arousal-induced amplification of loop gain. Many of these patients, again, if appropriate, certainly weight loss may be helpful, and these are among many things that we can potentially do to improve the ventilatory stability of these patients.  Dr Monteith: Okay, great. But let's also talk about the general overall approach to diagnosing, and much of it is by history, as you mentioned. There's also sometimes a need, as you say, to differentiate out how much is obstructive. So, what is the thinking process there when you're approaching a patient?  Dr Liu: So perhaps I can start with in terms of the diagnostic modalities that we could use for this. So, the gold standard for diagnosis of central sleep apnea is still our polysonogram. The home sleep apnea test sometimes may be harder to distinguish between obstructive and central events. In addition, on a PSG, you have EEG. This allows you to assess for sleep quality and arousals, as well as the EMGs, which can help you pick up periodic limb movements of sleep. And of course, all of these things themselves can affect the central sleep apnea and can be a potential treatment factor.  Dr Monteith: Before we get into treatment, can you just give us, like, the top five or six drugs or drug classes we need to look for so that, you know, we can discontinue or try something else for our patients that might be complicating their presentation?  Dr Liu: Certainly medications, in some cases, can help central sleep apnea, but other cases can certainly be a precipitant of central sleep apnea. So, one thing to consider would be opioid medication. They can certainly cause very complicated central sleep apnea, something called ataxic breathing, where you have irregularity to the tidal volume and the rate of breathing. Other medications such as Oxybate, baclofen, valproic acid, gabapentin, all of which can certainly contribute to central sleep apnea. And of course, in the stroke world, something that we should always think about is that Tetagelor can also contribute to central sleep apnea. And outside of this, things like muscle relaxants, anesthetic agents can also be a contributor.  Dr Monteith: Great. Now let's get into some of the treatment.  Dr Liu: I like to divide treatment into targeting a hypercarbnic central sleep apnea and a hypocarbonic central sleep apnea. For hypocarbonic central sleep apnea, the first line is CPAP treatment. But for many patients, CPAP therapy is insufficient. There's also adaptive servo ventilation, which is an advanced device designed for hypocarbonic central sleep apnea. For hypercarbic central sleep apnea, again, first line is CPAP treatment, with more advanced devices being a bilevel therapy as well as volume-assured pressure support ventilation. There are also medications that can reduce loop gain, with the most researched one being acetazolamide. We can also reduce arousal thresholds, which could be appropriate for certain patients. And for certain patients, improving arousal threshold can be helpful as, especially in hypocarbic central sleep apnea, that arousals can amplify loop gain. Weight loss can be helpful for both hyper- and hypocarbonic central sleep apnea, and we have great new medication on the market for this. Other therapy can include supplemental oxygen that can be added to PAP devices, as well as phrenic nerve stimulation, positional therapy, as well as carbon dioxide modulation.  Dr Monteith: Excellent. So, it sounds like there's a lot of opportunity to help patients. Now, what are you most excited about in terms of latest development for detection as well as for intervention?  Dr Liu: Thank you very much. I'm actually excited about many things in sleep medicine. Perhaps the thing that I'm most excited about in detection in sleep medicine would be the wearable technologies. So, these technologies may use photoplethysmography to detect peripheral artertonometry. This is where we're measuring the pulsatile arterial volume signals as a surrogate of cardiac and respiratory function. And when paired, that was often desaturation. With these technologies, we can actually detect the staging, autonomic arousals, and HI. So of course, these technologies do not have flow, and they do not have EEG. But they're very powerful technology that allows us to do multi-night testing from home. And of course, understanding both the potential limitation of these technology in the context of patients can be very useful. In terms of treatment-wise, we're learning so much about the underlying contributing drivers of different forms of central sleep apnea. So again, this is highlighted in my article that many of these patients needs multimodal targeted treatment, both between either a PAP device in addition to other things such as medication, oxygen, positional therapy, and so on.  Dr Monteith: Great. So, I mean, I think there's so much to this field. Your article is very extensive. Thank you very much for writing this. I know it may have taken a bit of time, and I appreciate you being on our podcast.  Dr Liu: Thank you very much.  Dr Monteith: Again today, I've been interviewing Dr. Richard Liu about his article on central sleep apnea. This article appears in the August 2026 Continuum issue on Neurology of Sleep. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio. 

Dr. Masud Husain is a Professor of Neurology & Cognitive Neuroscience at the University of Oxford and a leading expert on the science of motivation, apathy, and neurological diseases. We discuss how dopamine and specific brain circuits shape motivation, including how the brain weighs the trade-off between effort vs reward when deciding what goals to pursue. Dr. Husain also explains practical tools to increase motivation, reduce distractions, and make it easier to start and maintain goal pursuit. We also discuss dementia, Parkinson's and Alzheimer's disease, including new insights into cognitive resilience and factors that help protect against age-related cognitive decline. Show notes: https://go.hubermanlab.com/masud-husain-295 Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman BetterHelp: https://betterhelp.com/huberman Eight Sleep: https://eightsleep.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Masud Husain (00:02:24) Apathy, Motivation (00:08:07) Rewards, Apathy & Motivation; Dopamine (00:13:20) Sponsors: David & BetterHelp (00:15:44) Types of Apathy; Goal Prioritization: Effort vs Rewards (00:23:26) Motivation, Apathy, Tool: Activation Energy & Overthinking (00:29:24) Tools to Increase Motivation: Incentives, Subdivide Tasks, Planning (00:35:13) Subjective Effort, Mental Framing; Learning & Motivation (00:42:24) Sponsors: AG1 & Eight Sleep (00:44:54) Perseverance, Failure; Finding Your Passion, Depression vs Apathy (00:50:58) Self-Concept, Ambition; Life Satisfaction (00:58:25) Psychedelics, Anhedonia & Changing Self (01:03:09) Personal & Social Identity, Tools: Curiosity, Purpose & Dementia Risk (01:11:58) Addiction, Dopamine; Social Media & Dopamine "Hits"? (01:18:36) Sponsor: Function (01:20:13) Dopamine, Parkinson's Disease; Other Roles of Dopamine (01:26:59) Life Purpose, Culture; Reflection, Weighing Decisions (01:34:21) Internal & External Attention (01:39:59) Internal Chatter, Distraction; Working Memory, Stimulants, Nicotine (01:48:54) ADHD, Diagnosis; Attention & Motivation (01:54:34) Goal Planning & Perseverance (01:59:44) Alzheimer's Disease, Dementia, Apathy, Tools: Dementia Risk Factors (02:06:55) Neurodegenerative Disease & Emerging Treatments (02:10:59) Can You Train Attention?, Tool: Reduce Distraction (02:15:14) Enrichment, Art (02:17:45) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

In part one of this series, Dr. Greg Cooper talks with Drs. Trey Bateman and Gregg Day about blood-based biomarkers, anti-amyloid therapies, and other highlights from the 2026 Alzheimer Association International Conference.  Disclosures can be found at Neurology.org. 

Why would a neurologist recommend an infusion instead of a pill, and what should patients expect when they arrive for treatment? Neuro infusion therapy can be used for conditions including multiple sclerosis, myasthenia gravis and Alzheimer's disease, but the process can feel unfamiliar or intimidating at first.In this episode of Baptist Health Talk, host Dr. Anthony Gonzalez speaks with Janisse Marin and Leah Marcelin about how neurological infusion therapy works, why it may be recommended, and how care teams help patients through treatment. What neuro infusion therapy is and how it differs from chemotherapy  Why an infusion may be chosen instead of an oral medication  What happens before, during and after an infusion appointment  Common side effects and how patients are monitored for reactions  How infusion therapy is used for multiple sclerosis, myasthenia gravis and Alzheimer's disease  Why some treatments are designed to slow disease progression rather than immediately relieve symptoms  How education and a coordinated care team can make treatment less overwhelmingHost:Anthony Gonzalez, M.D.Chief of Surgery, Baptist Health Baptist HospitalMedical Director of Bariatric Surgery, Baptist HealthGuests:Janisse P. Marin RN, MSNChief Nursing Officer/Assistant Vice President Baptist Outpatient ServicesHalena Leah Marcelin, PharmDAssistant Vice President, Pharmacy Business Affairs & DevelopmentBaptist HealthIf you found this episode helpful, we recommend the following for additional information:Infusion Care for Osteoporosis: What Patients Should KnowThe Power of Infusion Therapy: What You Need to Know

Send us Fan MailToday we're releasing a new episode from a brand new series called the Boundless Body Radio Heritage Series! I wanted to do something extra special to celebrate 1,000 podcast episodes recorded here at Boundless Body Radio, a milestone that we hit on June 24, 2026!These episodes are actually not new, although they might be new to you! When we first got started back in October, 2020, I was so fortunate that so many incredible people said "YES" to being hosted on the show, however, we didn't have very many listeners at the time!Today, we get thousands of downloads every single month, and are usually included in the top 150 Fitness and Nutrition Podcasts on the Apple Podcast charts!To honor our amazing guests, I will be selecting one of those original episodes and posting them here on for this special series!As I was going through these episodes again, I remembered how valuable these conversations actually were. it was really striking how much the information these experts have shared has born out to be even more accurate several years later.The audio quality of a show was not as good back then as it is now, but I still really hope you enjoy these episodes, and find them relevant and helpful to you today!Cheers, thanks as always for listening, and I really hope you enjoy this episode of the Boundless Body Radio Heritage Series!Dr. Thomas Seyfried is a returning guest on our show! Be sure to check out his first appearance on Boundless Body Radio on episode 60, which one of the most fascinating discussions we've ever had, all about cancer as a metabolic disease! He was also hosted on episode 363 of our podcast.Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition.Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley, 1st ed., 2012).Find Dr. Seyfried at-https://foundationformetaboliccancertherapies.com/Movie, coming soon- CANCERREVOLUTION: A Cancer Science Documentary with Dr. Seyfried and former podcast guest Travis Christofferson.Find Boundless Body at-myboundlessbody.comFind Boundless Body at-myboundlessbody.comBook a session with us here! 

Dr. Shuvro Roy and Prof. Catherine Jutzeler discussed how age influences neurologic and functional recovery after spinal cord injury and how these findings could inform treatment and future clinical trials.  Show citation:  Pavese C, Scivoletto G, Puci M, et al. The Relationship Between Age and Recovery After Spinal Cord Injury: A Longitudinal Cohort Study. Neurology. 2026;106(2):e214516. doi:10.1212/WNL.0000000000214516    

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Pezhman Roohani, MD, neurologist and medical director of the teleneurology and telestroke program at Allina Health, joins the podcast to discuss the emerging role of GLP-1 receptor agonists across neurology. Roohani outlines where these therapies may have the greatest impact, highlighting stroke prevention, neurodegenerative diseases, idiopathic intracranial hypertension, and other areas being explored as researchers look beyond their established metabolic effects. The conversation also examines what recent Alzheimer disease trial results mean for the future of GLP-1 research, including the potential importance of prevention and identifying patient subgroups most likely to benefit. Roohani discusses key cautions surrounding long-term use, muscle loss, nutrition, and lifestyle modification, as well as practical considerations when counseling patients. He closes by highlighting unanswered research questions and potential applications in neuroinflammation, traumatic brain injury, and addiction. Looking for more Stroke discussion? Check out the NeurologyLive® Stroke clinical focus page.Episode Breakdown: 1:15 – Neurologic conditions showing the greatest promise for GLP-1 therapies 4:15 – GLP-1s in neurodegeneration following recent Alzheimer trial results 7:35 – Key cautions and limitations surrounding long-term GLP-1 use 9:35 – Neurology News Minute  11:50– Counseling patients on lifestyle changes when initiating GLP-1 therapy 14:20 – Research priorities and emerging neurologic applications for GLP-1s The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: First-Ever Platform Trial for Progressive Supranuclear Palsy Enrolls Its Inaugural Participant FDA Approves Tau PET Tracer MK-6240 for Alzheimer Diagnostic Workup Efgartigimod Meets Primary Endpoint in Phase 3 ALKIVIA Trial of Autoimmune Myositis Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Dr. Shuvro Roy talks with Prof. Catherine Jutzeler about how age influences neurologic and functional recovery after spinal cord injury and how these findings could inform treatment and future clinical trials. Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Dr. Greg Cooper and Dr. Chloe Hill discuss comparing virtual and in-person neurology outpatient visits for new patients. Show citation:  Hill CE, Lin CC, Harris A, et al. Virtual vs In-Person Neurologic Ambulatory Care: A Case-Control Study of Subsequent Health Care Utilization. Neurology. 2026;106(10):e214989. doi:10.1212/WNL.0000000000214989 

Rebecca Haffajee is a professor in the Department of Health Policy and Management at the Yale School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. R.L. Haffajee, R.A. Mikos, and Z.D. Cooper. Marijuana Rescheduling — A Game Changer for Research? N Engl J Med 2026;395:729-731.

Advances in sleep technology are transforming how neurologists identify and manage obstructive sleep apnea, a condition that affects up to 70% of patients with certain neurologic disorders and can negatively impact cognitive and neurologic outcomes if left untreated. In this episode, Dr. Joyce Lee-Iannotti discusses the growing role of wearable and nearable sleep-monitoring devices, when home sleep studies are appropriate, and how emerging technologies are expanding access to diagnosis and treatment. Learn practical strategies for screening patients, interpreting sleep data, and partnering with sleep specialists to improve long-term neurologic health through better sleep. In this episode, Casey S. Albin, MD, FAAN, speaks with Joyce K. Lee-Iannotti, MD, FAAN, FAASM, author of the article "Sleep Diagnostics and Monitoring Technology in Obstructive Sleep Apnea" in the Continuum® August 2026 Sleep Neurology issue. Dr. Albin is a Continuum® Audio interviewer, associate editor of media engagement, and an assistant professor of neurology and neurosurgery at Emory University School of Medicine in Atlanta, Georgia. Dr. Lee-Iannotti is a Professor of Neurology at the Barrow Neurological Institute, University of Arizona College of Medicine, and Creighton School of Medicine in Phoenix, Arizona. Additional Resources Read the article: Sleep Diagnostics and Monitoring Technology in Obstructive Sleep Apnea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @caseyalbin Guest: @jleeiannotti Full episode transcript available here Dr Albin: Through the neurology of sleep issue, I think we have all been convinced that we all need better sleep, both for ourselves and for our patients. And fortunately, there is an abundance of new technology that can enable us to diagnose sleep problems, and then also make sure that our patients are getting the rest that's going to give them the best chance at a good cognitive recovery, and improve their cognitive function even if they are not currently suffering from a neurologic condition. Today, I am so excited to dive deeper into this topic.  Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Albin: Hello, this is Dr. Casey Albin. Today I'm interviewing Dr. Joyce Lee-Iannotti about her article on sleep diagnostics and monitoring technology in obstructive sleep apnea. This article appears in the August 2026 Continuum issue on neurology of sleep. Welcome to the podcast, I'd love to just start by having you introduce yourself to our audience.  Dr Lee-Iannotti: Sure. Thank you so much for having me, Dr. Albin. I'm Joyce Lee-Iannotti. I'm a professor of neurology at Barrow Neurological Institute. I am boarded in general neurology, stroke, and sleep, but I spend most of my time in the sleep world, so I jokingly say that I get more sleep doing sleep than I certainly did in stroke.  Dr Albin: Absolutely. I mean, wow, what a fascinating career, and I suspect that we're actually gonna get to some of how all of those pathophysiologies might overlap in the world of sleep. But you had the really exciting task of trying to distill this exciting, rapidly evolving field of sleep diagnostics, and I suspect it's relevant to many of the patients who end up in the neurology clinic, and I suspect that it's actually pretty relevant to many of our listeners who themselves might actually be wearing sleep tracking devices. And all of us probably wonder, well, how can we use that data to improve our own cognitive function and certainly make our patient's life even better? Before we even get into some of the meat and potatoes of this, I thought it would be really helpful for us to define some terms that come up in your article, one of which is wearables. We might figure that out, but the other is nearable. Walk us through what's a wearable, what's a nearable, how are they different?  Dr Lee-Iannotti: I'm happy to do that. First of all, the article is entitled Sleep Diagnostics and Monitoring Technology, and this was a super fun article for me to write because it's very practical, and it's generalizable to everybody. So, I'm going to start with a wearable, and a wearable is really a device that is simply worn on the body. And we're all familiar with wearables like smart watches, they're rings, they're patches, they're headbands, and the most validated form of a wearable that you've probably heard about is actigraphy, which we use in the sleep clinic.  Dr Albin: Tell us a little bit more. So, what is actigraphy? I've heard the word before, but don't actually know what it means.  Dr Lee-Iannotti: Actigraphy has been a tool that we've used in the sleep clinic for a really long time. Traditionally, we used it to monitor circadian rhythm patterns in people who are night owls or morning larks. And then more currently, we actually use it to track sleep patterns in people with suspected narcolepsy. So, before they come in for a sleep study, we actually have them wear an actigraphy for about a week just to get a sense of their sleep duration and their circadian pattern.  Dr Albin: Got it. And what is it monitoring? Our movement or the patterns that we may or may not make?  Dr Lee-Iannotti: It's really based on movement. You're exactly right.  Dr Albin: Cool. Okay, so most of this is based on gold standard monitoring with actigraphy. What other things can be incorporated into these wearable devices?  Dr Lee-Iannotti: Yeah, the technology is really advanced, and every day it changes, which is super exciting. So, on top of movement, these wearables can look at temperature. They can look at even EEG, like limited EEG, heart rate variability, and a really big word that we like to use in sleep technology, which is PPG, or photoplethysmography data, and that's really looking at heart rate variability and oxygenation, saturations, and following those levels as well.  Dr Albin: Wow, so you basically can get most of the data that you might have historically needed to go to a sleep lab to get.  Dr Lee-Iannotti: Most of them. They're still a surrogate. You'll hear me emphasize in the article as well that the gold standard remains the in-lab polysomnogram, but these are good surrogate markers that patients can wear long term to look at trends and patterns.  Dr Albin: Absolutely. And we're gonna unpack a little bit about who specifically those are best for and, really what it gives you in the clinic. But before we jump into that, what's a nearable, and how is that different?  Dr Lee-Iannotti: Yeah. Nearables are really exciting too. So, these are devices that monitor sleep but don't require direct contact on the body. So, these are devices that our patients will use, but it'll be at the bedside table. They're devices that actually go underneath the mattress, or they can be in, like, the ambient environment to detect sleep patterns.  Dr Albin: Oh my gosh. How is it doing that if it's not actually something you're wearing? Dr Lee-Iannotti: I know. It seems a little Big Brother-ish, doesn't it?  Dr Albin: Yes.  Dr Lee-Iannotti: So, they use a technology called radio frequency signals, sometimes radar, sometimes sonar, pressure sensors, even microphones, and they're picking up things like respiration, movement, snoring, and that's how they can decipher sleep patterns.  Dr Albin: Crazy. I mean, I guess the benefit of that is that it's less disruptive to the user 'cause it's not actually on them and having contact with them, and I suspect there's probably some downsides in terms of just it's a more limited data set you're getting.  Dr Lee-Iannotti: Absolutely. Yeah, you're exactly right. It's more convenient because it's not touching them, so, in theory, they're gonna sleep more comfortably. But I would like to think that the most validated forms of devices that we use to track sleep have to have some form of contact with the body, and this technology is new and probably needs a few layers of more sophistication to be as accurate as the wearables.  Dr Albin: Absolutely. I feel like we're going to have this conversation in five, maybe even less than that, years, and this data will have become like, oh, we all have something in our room that's monitoring everything. The world is crazy. All right. One of the places where your article really stood out to me is that sleep diagnostics have really taken off, particularly when we're thinking about obstructive sleep apnea. And I think we all might sort of scratch our heads and be like, "This is a neurology podcast. Why should I, as a neurologist, care about obstructive sleep apnea?" But I think you laid out a very convincing argument in the article. Walk us through why we should care about this.  Dr Lee-Iannotti: Absolutely. So, for neurologists, sleep matters, and I hope that my article translates that. Obstructive sleep apnea, which I'm gonna call OSA, is incredibly common in all of our neurologic patients, whether you see epilepsy, Parkinson's, stroke, Alzheimer's, neuromuscular, or even chronic headache patients. The prevalence of sleep apnea is as high as 70% in these patients.  Dr Albin: Wow. That's incredible. That is an incredibly high number.  Dr Lee-Iannotti: And if I can add, Dr. Albin, there's growing literature in multiple studies across the literature that show that untreated sleep apnea negatively impacts neurologic outcomes in our patients. So, it is really important to ask the question about sleep, and if the red flags pop up, to then screen for sleep apnea in particular.  Dr Albin: I think that that's a great point for us to drill down on, and obviously you're a sleep neurologist. You're very used to screening people in the clinic. But say someone comes in, and I'm gonna have you put your former stroke hat on, and say someone comes into the stroke clinic, and you're just making sure that they're optimized on their aspirin or dual antiplatelet therapy, and you're doing secondary risk modification. How would screening for OSA fit into that?  Dr Lee-Iannotti: It would be a part of that screening process to look at preventative ways to prevent strokes, whether it be primary or secondary prevention. So, we did a survey a while back, and it actually showed that 17% of stroke neurologists are screening for sleep apnea. It has quadrupled, fortunately, in the last few years due to public awareness and a lot of education that the AAN has done, in fact. So, at this point, I would say not asking about sleep apnea to a stroke patient is similar to not asking about diabetes.  Dr Albin: So, we really have to be cognizant and conscious about saying, you know, "Do you snore at night? Do you have episodes of apnea, or does someone witness you stop?" Are there things that you ask that maybe I wouldn't be aware and thinking of?  Dr Lee-Iannotti: Those are the right questions, and then very practically, very easy questionnaires to implement that literally take a minute that your nurses or medical assistants can administer to the patient, and the most commonly one that is used in stroke patients is called the STOP BANG, S-T-O-P B-A-N-G, which is a validated questionnaire to screen for symptoms.  Dr Albin: Absolutely. So okay, so this is easy to do. We should all be doing this. If you're not, now's the time. And I suspect if they screen positive, next steps, it can be hard to get into a sleep lab, and we're gonna talk about some workarounds, but I think some of our listeners may never have spent time in the actual sleep lab. So, let's say you refer a patient and you actually can get them in for a gold standard in-lab sleep study. What's gonna happen in that sleep study?  Dr Lee-Iannotti: Yeah. And I just want to preface this by saying that my article hopefully highlights that we've come a long way where we understand that there are many neurologic populations then that can undergo home ambulatory sleep studies with just as much accuracy as an in-lab polysomnogram. But with that, I wanna say an in-lab polysomnogram is actually a highly sophisticated physiologic recording overnight, typically, unless somebody is a day sleeper. So, if I could take a minute to kinda describe the data that we're monitoring throughout the night. There is a limited EEG. We concentrate on frontal, central, occipital leads to look at sleep staging. We have eye leads. We have EMG leads on the chin and the leg. We look at EKG, flow monitors, belt, and then we also do pulse oximetry, snoring mics, and even body position sensors. So, a lot is going on.  Dr Albin: This is incredible. Yeah, it truly is. I mean, this is like... I'm a neurointensivist, and so I think that you have just really outdone what I consider multimodal monitoring in your sleep study patients. I'm not even sure our neuro ICU patients accumulate that much data. All right, so tell me, they go through, and they can get this. But like you said, there's actually a lot of data that you've presented that, you know, not everyone needs to go to the in-lab sleep study. So how do you decide who actually needs to be in a sleep lab versus who can do this at home? And then how do you set them up with getting this done at home?  Dr Lee-Iannotti: Yeah. The home sleep studies are really more accessible ways for us to assess for sleep apnea in our neurologic patients, especially patients who live in very rural areas and don't have access or have very long wait times for an in-lab polysomnogram. With that being said, though, Dr. Albin, I will say that there are a subset of patients who have to go into the lab, and those are patients where you suspect a sleep disorder other than obstructive sleep apnea, so like parasomnias or central sleep apnea, patients with severe cognitive or physical debilitation, like our stroke patients who are hemiplegic and won't be able to apply the home sleep study. But for the most part, I do feel like a home sleep study is a good beginner study to screen the patient. And if there are red flags, then you can always get the in-lab afterwards.  Dr Albin: That's super helpful. And just from a pragmatic standpoint, will insurance cover the home sleep study?  Dr Lee-Iannotti: They will, yes, and it's all about documenting. So, if I could get really practical, for neurologists, it really just requires documenting snoring, for one, whether it's noted by the patient or by their bed partner, and then any form of hypersomnia, which is daytime sleepiness or even a sense of fatigue, having low energy or napping during the day.  Dr Albin: I suspect so many of our patients meet those criterias. That seems, like, wildly simple to do.  Dr Lee-Iannotti: Yes. And if you wanna be the favorite referral person to your sleep neurologist or your sleep specialist, then take another step and do that STOP-Bang. And if you record a score greater than three, that automatically gets them at least a home sleep study.  Dr Albin: It's amazing. And then when you get this data, again, this is really practical, pragmatic stuff, how do you get the report? Does it integrate in your electronic medical record? Does the patient bring it in? How do you get that data back?  Dr Lee-Iannotti: Yeah, so this is where technology is amazing, Dr. Albin. Now we have disposable devices. Sometimes they sync to the WatchPat, or the greater Wi-Fi. So we can get them all through password-protected internet forums that transmits the data, so sometimes the patients don't even have to come back to give us the data. And then we have different forms where we can actually relay the results as well, either through the electronic medical record or through systems themselves to relay those results directly to the patient.  Dr Albin: Yeah, and your article really laid out in beautiful tables, like, all the different devices that are available to patients, and it's honestly mind-blowing how many of these companies and devices exist. So, seems like the world is your oyster in terms of picking from them.  Dr Lee-Iannotti: Absolutely. I think there's... The last time I counted, there was over 20 different home sleep study devices for obstructive sleep apnea. And it's a great thing to have, but sometimes too many choices can be a little bit confusing. So that's where I do say partner with your sleep specialist close by, and they will find the right type of home sleep study device for your particular patient.  Dr Albin: Drilling down a little further, let's say your patient does get diagnosed with OSA. One of the things that really stuck out to me is that there's a whole range of now devices that are new that make this treatment easy so that we can actually prevent and treat neurological conditions by just improving patient sleep. So, walk us through a little bit about how that landscape has changed.  Dr Lee-Iannotti: Sure. And I'll start with the gold standard of treatment, which is still CPAP, which is continuous positive airway pressure. Not only can we monitor the pressure, look at adherence, change the humidification for the patient all remotely through, again, password-protected internet forums, but we can even change the pressure with patients 300-plus miles away.  Dr Albin: Wow.  Dr Lee-Iannotti: It's really cool, right? It prevents patients, especially with significant neurologic debilitation, from having to come into the office for adjustments. The other thing I wanted to mention, Dr. Albin, is for patients, a lot of patients like positive feedback on a daily basis. And a lot of these companies, if you are on CPAP, have come up with a smartphone app that you can look at how many hours you used your CPAP device. They give you a score, and they even tell you how many times you had stoppage of breathing that night.  Dr Albin: I think that this is what's really exciting about where we are in neurology and, like, neurologic care, is we have gotten so much better at getting patients their own data and allowing people to really see that data, integrate lifestyle changes, and see how it impacts them. And that positive feedback loop, I think, is a really powerful tool for our patients to say, "Look, this makes me better," or, "Oh, this makes me worse." I'm just really excited by how much data we can give directly to our patients.  Dr Lee-Iannotti: I agree. It's so empowering. You know, as a CPAP user myself, you want that positive affirmation that all of your efforts at night and cleaning your mask and your machine paid off, and everybody likes to see an A+ on their report card.  Dr Albin: I love that. Now I'm going to ask you on the flip side, I imagine, and I myself am a sleep tracker, like I have my little device and I look at, you know, the score in the morning and I kind of perseverate on like what makes it better, what makes it worse, and I can imagine that sometimes in sleep clinic, people are coming in to you and they have just pages and pages and, you know, they're flipping through all their data from the last year. And I imagine that's pretty overwhelming when you have just the insane amount of data that these devices can generate. So, from another pragmatic, practical standpoint, how are you integrating all that data when someone comes in for a sleep visit?  Dr Lee-Iannotti: I love that question. So first of all, I will say myself, and I think a lot of my sleep colleagues, we love objective data, right? Because it's something that we can see. We can see whether it matches their subject's symptoms. Sometimes it can be a lot of reassurance that, "Look, you actually got more sleep than you thought you did." But sometimes patients will bring in like a month's worth, and that's really hard to analyze, you know, in a 30 or 60-minute visit. So oftentimes what I do is I look at like the last week or last two weeks, and I look at trends. And I think a lot of the apps for whatever device you decide to use have done a really good job in terms of visual graphics to show how much sleep on average you're getting, how much deep sleep or REM sleep or wake-up times that you have. So, I, again, I feel like the technology has really helped us consolidate a lot of data, but also be efficient with the messaging that we relay to our patients.  Dr Albin: Absolutely. And I know personally, at least for the sleep tracker I wear, it also allows you to diary. So, you can say like, "Oh, last night I had a glass of wine," or, "Yesterday I had a really hard workout," or, "I stayed out late with friends," or, "I was on call." Turns out call is really, really bad for my sleep. But it does allow you to sort of track what behaviors, and I wonder how much of that informs what you're counseling patients to do in terms of trying to notice the things that either improve their sleep performance or their subjective feeling of restlessness or restfulness, and how all of that plays into what you're doing in the clinic.  Dr Lee-Iannotti: I love all of those comments. It is validation for the patient. Again, it's empowering for them to look at, what did I do last night to get more REM sleep than the night prior? I want to mention that the best people who do this so well are professional athletes, and they look at, how am I going to cater my day to make sure that I'm sleeping well, that I reduce my risk of injury and concussion and increase my reaction time? And I feel like all of us should do that. That's such a great philosophy, to analyze how we can do things better.  Dr Albin: I love that. This whole issue, but this article in particular, really emphasized to me that sleep, again, it's not a passive time that we're taking a nap. It's a really active form of sort of neurologic healing. There's important removal of toxins through the lymphatics. And like there's a lot happening in sleep, and there are so many more tools that allow us to unpack that sort of peak performance of sleep, which again, sort of is that athletic mentality of like, how can I make this better? Not just to treat a neurologic condition, but also really importantly, to prevent one.  Dr Lee-Iannotti: I often refer to sleep as icing on the cake. With our patients, when you're doing everything right, for example, a multiple sclerosis patient, they're on the right medications, they are exercising, they're participating in rehab, their mood is good, but they're just not getting to the quality-of-life metric that they want to be, it usually is sleep. And if you can add that as a neurologist to your piece of the algorithm to help your patient, it really does improve their quality of life and ultimately their neurologic outcome. I'm a true believer of that.  Dr Albin: I was a true believer. I've been made even more of a true believer through your article and getting to talk to you. I always like to close by asking the person I'm interviewing, what's one really exciting thing in this field? What are you kind of most looking forward to as you think about sleep medicine and its impact in neurology in the next five or 10 years?  Dr Lee-Iannotti: Oh, I love that question, too. So, the thing I'm most excited about in the field of sleep, and specifically sleep neurology, is the power of preventative care. When I did a lot of stroke, I would see young people, older people, healthy people, people with a lot of genetic risk factors come in, and one minute they were totally normal. The second minute, they're paralyzed and can't speak. And for a lot of these patients, I would ask, "Why am I seeing you now? Why couldn't I have seen you 10 years earlier, worked on risk factors, and prevented this outcome?" And I truly believe that is exactly where sleep lies. If you work on sleep, whether you're an adolescent, 20 year old, 30, et cetera, you are ultimately going to prevent horrible cardiovascular, cerebrovascular, neurologic diseases in the long run.  Dr Albin: So important. I really want to direct our listeners back to your article because all of the articles are really practical, but this one in particular looks at how do you do this? What are your options? How do you get this to patients? It really is sort of a step-by-step guidebook on like, A, why this is important, how you should screen, what you should do if someone screens positive for needing to have a sleep study.There's so much more technology that allows really anyone anywhere to have access to the testing that they need to get the right diagnosis, to improve their sleep, to improve their cognitive outcomes, to improve their neurologic health. It's pretty amazing.  Dr Lee-Iannotti: It is amazing. And in the article, I do allude to certain devices and then websites that are very helpful. If I can announce, Dr. Albin, I'm super excited about this. Through work with the American Academy of Sleep Medicine, endorsement with the AAN, we are coming out with a new clinical guideline specifically on home sleep study devices and looking at the validation studies. So, I think that's going to be very helpful. But I hope that everybody after listening to this picks up the phone, call your friendly sleep specialist, and align with them and partner with them. And this will ultimately help your patients, I guarantee it.  Dr Albin: Again, today I've been interviewing Dr. Joyce Lee-Iannotti about her article on sleep diagnostics and monitoring technology in obstructive sleep apnea. This article appears in the August 2026 Continuum issue on Neurology of Sleep. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners, and thank you, Dr. Lee-Iannotti, for joining us today. Dr Lee-Iannotti: Thank you.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audiocme. Thank you for listening to Continuum Audio. 

In this session, attendees will be equipped to navigate the discernment process of identifying the best-fit sending agency for them.

Dr. Margarita Fedorova talks with Dr. Sunanjay Bajaj about the Consortium of Neurology Residents and Fellows (CNRF).  Visit the AAN website to learn more about the CNRF.  Connect with the AAN's Consortium of Neurology Residents and Fellows on Synapse. 

Dr. Greg Cooper talks with Dr. Chloe Hill about comparing virtual and in-person neurology outpatient visits for new patients.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Dr. Aaron Zelikovich discusses the efficacy and anthropometric effect of vamorolone with prednisone and deflazacort. Show citation:  Clemens PR, Berglund A, Schiava M, et al. Vamorolone for Duchenne Muscular Dystrophy: A Cross-Trial Efficacy Comparison With Classic Corticosteroids From the FOR-DMD Trial. Neurology. 2026;107(1):e214756. doi:10.1212/WNL.0000000000214756 

Dr Rachel Forman is an Assistant Professor of Neurology at Yale School of Medicine and a stroke neurologist at Yale New Haven Hospital. She tells us signs to watch out for and how to make sure you are preventing having a stroke.

We continue our campaign to #EndNeurophobia, with the help of Dr. Helen Shi. This time, Gillian presents a case of a 56 year old man found wondering naked in grocery store. The discussants are Aye and Vale. Gillian is a second-year medical student at the Icahn School of Medicine at Mount Sinai in New York.… Read More »Episode 471: Neurology VMR – Found wondering naked in grocery store

A Fun one.Email me at GodsEyeViewBook@gmail.comLinks to some awesome interviews below:Andrew Gallimorehttps://www.youtube.com/watch?v=nshX-5xjTlABernardo Kastruphttps://www.youtube.com/watch?v=DrMEL20o5KEThis wasn't mentioned in the show but it just happened to be the next show in my youtube queue and it is hyperrelevant:Anil Sethhttps://www.youtube.com/watch?v=HYUoS0GkGCs

Dr. Dara Albert talks with Dr. Daniel Freedman about the new practice guideline from the American Epilepsy Society on infantile epilepsy, highlighting key findings on medication, dietary therapy, and the importance of early surgical intervention for infants with epilepsy.  Read the related guideline here.   Disclosures can be found at Neurology.org.   

Transcranial magnetic stimulation (TMS) is one of the most promising new technologies in psychiatry. Essentially, it allows us to reach inside the brain, stimulate it, and alter the brain circuits that go awry in disorders like depression. As the late Nolan Williams once explained, we've known for a long time that mental health disorders are caused by changes in electrical circuits in our brains, until TMS came along, we didn't had a good way of nudging those circuits back toward healthier function.But for all its promise, there is still much we don't understand about what exactly TMS is doing. We know it sends electromagnetic waves into the brain and changes the flow of electricity within. What we don't know is how it changes brain circuits and networks or why that helps treat depression, obsessive-compulsive disorder, or any of the other conditions where it's being used.Today's guest, Corey Keller, is dedicated to addressing that gap. He's been developing methods for recording inside the brain to help us understand how treatments like TMS change our brain circuits and address psychiatric disease.Learn moreStanford Precision Neurotherapeutics LabKoret Human Neurosciences Community LabClosed-loop Optimized rTMS for Depression (Stanford Medicine Clinical Trials)Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neuromodulation in Depression (Stanford Medicine Clinical Trials)Non-invasive brain stimulation opens new ways to study and treat the brain (Wu Tsai Neurosciences Institute, 2025)Music supercharges brain stimulation (Wu Tsai Neurosciences Institute, 2025)How brain imaging is transforming mental health (From Our Neurons to Yours 2025)Psychiatry 3.0 (From Our Neurons to Yours, 2023)Stanford Psychiatry's Corey Keller Awarded Grant to Research Biomarkers to Improve Efficacy of rTMS for Treatment-Resistant Depression (Stanford Medicine Psychiatry and Behavioral Sciences, 2026)Personalizing Brain Stimulation for Psychiatric Disorders: From Circuits to Closed-Loop Control (American Journal of Psychiatry, 2026)Transcranial magnetic stimulation with intracranial recording in humans and primates: a review (Brain: A Journal of Neurology, 2025)Neural effects of TMS trains on the human prefrontal cortex (Scientific Reports, 2023)Send us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.We want to hear from your neurons! Email us at at neuronspodcast@stanford.eduLearn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn. 

In this episode of the Brain & Life Podcast, co-host Dr. Daniel Correa is joined by actress, comedian, playwright, and storyteller Lauren Weedman. Lauren discusses her diagnosis of Bell's palsy after developing a sudden facial paralysis while filming in 2024 and how it changed her outlooks on work, motherhood, and mental health. Dr. Correa is then joined by Dr. Gary Gronseth, Professor and Chair of Neurology at the University of Kansas School of Medicine. Dr. Gronseth explains what Bell's palsy is, why it happens, what recovery typically looks like, and why some people—like Lauren Weedman—continue to experience lasting symptoms long after the initial diagnosis.   Additional Resources "This Is a Good Face": Lauren Weedman on Life After Bell's Palsy Bouncing Back from Bell's Palsy What Doctors Know About Bell's Palsy   Brain & Life Podcast Episodes on Similar Topics Playwright Sarah Ruhl Finds Inspiration in her Bell's Palsy Journey   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media Guests: Lauren Weedman @lauren_weedman Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

Obstructive sleep apnea affects approximately one in four adults and is especially common among patients with neurologic disorders, including stroke, Parkinson disease, dementia, epilepsy, and neuromuscular conditions. In this episode, Dr. Stephanie Stahl discusses why neurologists should routinely screen for OSA, highlights key symptoms and risk factors, reviews important considerations when interpreting sleep studies, and outlines current treatment options beyond CPAP. Learn how recognizing and treating sleep apnea can improve quality of life, optimize management of neurologic disease, and reduce long-term health risks. In this episode, Aaron L. Berkowitz, MD, PhD, FAAN, speaks with Stephanie M. Stahl, MD, FAASM, author of the article "Obstructive Sleep Apnea" in the Continuum® August 2026 Sleep Neurology issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Dr. Stahl is an Associate Professor of Clinical Medicine and Sleep Medicine Fellowship Program Director at Indiana University School of Medicine in Indianapolis, Indiana, where she also serves as Sleep Laboratory Medical Director in the Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine. Additional Resources Read the article: Obstructive Sleep Apnea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz  Full episode transcript available here Dr Berkowitz: Obstructive sleep apnea is very common. It can cause or contribute to common neurologic symptoms, such as headache and impaired cognition, and it's a risk factor for stroke. And yet, if you're like me, you may not know too much more about sleep apnea than that. Today, I have the pleasure of talking to sleep expert Dr. Stephanie Stahl to learn what every neurologist should know about OSA.  Dr Jones:  This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Berkowitz: This is Dr. Aaron Berkowitz. Today I'm interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the 2026 Continuum issue on Neurology of Sleep. Welcome to the podcast, Dr. Stahl, and could you please introduce yourself to our audience?  Dr Stahl: Yeah. Thank you for having me. I'm a sleep medicine physician and neurologist and medical director of the Indianapolis Sleep Lab at Indiana University Health. I serve as the director of the Sleep Medicine Fellowship program. I'm faculty advisor for our very first student interest group in sleep medicine at Indiana University School of Medicine. I'm also actively involved in some national leadership roles, including the incoming chair of the American Academy of Sleep Medicine's Education Committee and co-chair of the Academy's Inter-Scorer Reliability Gold Standard Panel. So, I really appreciate this opportunity. I look forward to our discussion.  Dr Berkowitz: Me too, and we appreciate the opportunity too to get to talk to you. You have so much expertise in this area, and I certainly encourage our listeners to look at your article, which is very comprehensive and up to date, and I learned a ton from it. I didn't get much exposure to sleep neurology as a trainee, and I've always worked in academic centers where we have a sleep group and we can refer patients there. So, I have to admit, sleep may probably be the area of neurology I know the least about, and felt like I was learning something new from pretty much every line of your article, and I know our readers will too. So, your article has a lot of excellent detail for our readers on the diagnosis and treatment of this very common condition. But I'd like to keep our interview relatively high level today and focus on the essentials for the practicing general neurologist. So, to start, can you just give us a sense of what obstructive sleep apnea is, and what every neurologist should know about it?  Dr Stahl: Yeah. So obstructive sleep apnea is characterized by either partial or full obstructions in the upper airway. That may sound pretty simple, but this leads to a whole bunch of issues. It leads to oxygen desaturations, arousals from sleep, leading to sleep fragmentation. This can then lead to sympathetic nervous system activation, cerebral hypoperfusion, leading to a whole bunch of symptoms or neurologic conditions.  Dr Berkowitz: Great. And you mentioned this in your article, but just to emphasize, how common is obstructive sleep apnea in the general population?  Dr Stahl: Yeah. So, about a quarter of the general population have obstructive sleep apnea. Much more common in many neurologic conditions.  Dr Berkowitz: Yeah, so very common disorder. We are seeing patients with it quite frequently, whether that's the reason they are seeing us in neurology or not. And this leads to my next question, which is what neurologic symptoms or presenting concerns of a patient should make us think about OSA and the differential diagnosis, and what factors based on the history or the exam or the context would make you suspicious for OSA as the cause of a neurologic symptom? In other words, the patient's presenting with classic symptoms of OSA, and that's why they're seeing a neurologist or seeing a primary care doctor, but is coming for evaluation of, say, headache or other symptoms. And what symptoms would make you think of wanting to consider OSA, and then what aspects of the history or otherwise would make you want to evaluate the patient for OSA?  Dr Stahl: I think a really important takeaway is for neurologists to know that obstructive sleep apnea is very common in neurologic conditions and has that potential to worsen a lot of these conditions or their associated symptoms. And so, it should be on our radar. There are certainly some basic questions and signs and symptoms that we can ask patients about or, or take a look at on exam. And so particular symptoms include snoring. Anybody that snores loudly or frequently, that's a strong risk factor for obstructive sleep apnea. If someone's seeing them stop breathing in their sleep, if they are waking up a lot throughout the night. There are some other symptoms that we may not necessarily attribute upfront to obstructive sleep apnea, such as nocturia, nocturnal reflux, night sweats. There are some daytime symptoms, of course, too, like unrefreshing sleep, daytime sleepiness, morning headaches, an important one in neurology. And then we take a look at the patient's exam. And so, some things that neurologists might want to be thinking about are people with obesity are certainly at a risk for obstructive sleep apnea. But it's also very important to know that someone does not need to have obesity in order to have obstructive sleep apnea. We look at neck size, other morphologic characteristics, such as how much that we can see in the back of their mouth. Can we see their uvula? Does their tongue size appear large in their mouth? And then some other risk factors too, such as male gender, older age, family history, post-menopausal state in women. All that being said, though, sometimes in neurologic conditions, we don't have all of those symptoms or risk factors to be thinking about. And so, in certain neurologic conditions such as stroke where obstructive sleep apnea is very common and has the potential to increase the risk of another stroke, we may need to be thinking about testing these patients even with minimal symptoms or other risk factors.  Dr Berkowitz: That's very helpful. So, you mentioned their headache might be the presenting symptom, right, to a neurologist, and we should certainly be thinking about obstructive sleep apnea as a potential diagnosis, even the cause of the patient's headache, particularly you said patients with morning headache. I often try to think about in patients presenting with, for memory loss, or other cognitive concerns, and that may be due more to inattention from poor sleep, so asking about sleep and symptoms of sleep apnea in those contexts. Are there any other presenting neurologic symptoms not particularly related to sleep? I'm thinking of headache, memory loss, other symptoms that would make you think, "Oh, I should actually screen this patient for sleep apnea also."  Dr Stahl: Yeah, other symptoms to think about in pediatrics, hyperactivity, people that have impaired vigilance, as you alluded to, that poor attention. Sometimes people get misdiagnosed with ADHD, and it's actually just a manifestation of obstructive sleep apnea.  Dr Berkowitz: You alluded to this, Dr. Stahl, that stroke, for example, patients are at higher risk of developing sleep apnea as a result of stroke, and it's also a risk factor for stroke. What other neurologic conditions, primary neurologic diseases, put patients at a higher risk of OSA? And again, similar to the last question I asked you, what are some clues that we should evaluate for? We might be following a patient for their post-stroke care over time and not necessarily thinking about diagnosing a separate condition in them since we're following them for their stroke or their degenerative disease. What are the conditions that put patients at a higher risk of OSA as a result of the condition, and then when would you think about screening them for it?  Dr Stahl: Some particular neurologic conditions where obstructive sleep apnea are very common, in addition to stroke and, and TIA, include Parkinson disease. It can worsen a lot of the motor, cognitive symptoms, sleep disruption that we can see in Parkinson disease. Very common in all causes of dementia, but in particular Alzheimer disease and Lewy body dementia. Very common in neuromuscular conditions. We should definitely have obstructive sleep apnea and all forms of sleep-disordered breathing high on our radar. In conditions like myotonic dystrophy. Charcot-Marie-Tooth is another one where obstructive sleep apnea is very common. Myasthenia gravis, it can worsen the symptoms of that. In particular, a pearl is if somebody has morning weakness in myasthenia gravis, obstructive sleep apnea should be high on your radar. And also, as you mentioned, any forms of headaches. There are some other things too. If somebody has poor seizure control, especially nocturnal seizures, you might have obstructive sleep apnea on your radar as well.  Dr Berkowitz: So, I think you've covered essentially every category of neurologic disease, right? We have cerebrovascular, movement, neurodegenerative, neuromuscular, epilepsy, all conditions where either the disorder itself, such as stroke or the, correct me if I'm wrong, the neurodegenerative disease puts the patient at risk. Or the patient may be at risk for exacerbations of their disease, as you mentioned in myasthenia. I love that pearl. Not fatiguable at the end of the day, but if the patient with myasthenia is telling you they're feeling weaker at the beginning of the day, then think about obstructive sleep apnea and that obstructive sleep apnea worsening control of epilepsy due to poor sleep. So really a lot of bidirectional interactions with this common condition. Okay, so if we're concerned about obstructive sleep apnea, again, myself, a general neurologist speaking perhaps on behalf of other general neurologists, we see a patient with headache or reporting memory loss that we find to be impaired attention, or we see exacerbation of their underlying primary neurologic disease. As you mentioned, we think, "Oh, I've listened to this podcast. I've read Dr. Stahl's article. I should probably be thinking about OSA in this patient, and I should order a sleep study." Now, I admit when I get the sleep study back, I scroll to the bottom, I see they do have obstructive sleep apnea, I'm going to send them over to a sleep specialist. But for the general neurologist, what are some high-yield pearls and some pitfalls to be aware of when we get sleep studies for obstructive sleep apnea, and we are looking at the results? Dr Stahl: The first thing is to understand that there are two main types of sleep studies: in-lab polysomnography and home sleep apnea test. In-lab studies are typically what we consider the more accurate type of study. Main reason for that is that we have EEG, so we can see if someone is awake versus asleep. Most home sleep apnea tests do not utilize EEG, and so when we're looking at respiratory events, apneas or hypopneas, we're looking at over the total recording time rather than the total sleep time. So, we know we're going to capture some time where a person is awake, where we don't have sleep apnea events, and that can be a big amount of time in people with insomnia, poor sleep efficiency. And as a result of that, it can lead to an underestimation of the apnea-hypopnea index. That's really important for people to understand that that means we can end up with a false negative home sleep apnea test, or it can put them in a category of lower severity than what they actually have. And so, if you get a home sleep study report back that's negative for sleep apnea and you remain concerned, you need to go on to do an in-lab study, where about twenty to fifty percent of people will go on to have a positive in-lab study. You can also get false positives with home sleep apnea tests too, and so ideally, we should only be doing home sleep apnea tests in people that are at high risk of having obstructive sleep apnea to decrease our chance of false positive study. When we get that sleep study report, what's important to take a look at? So the main number that we look at currently is the apnea-hypopnea index. The number of apneas, which are full obstructions in that upper airway, or hypopneas, partial obstructions in the upper airway where either there's an oxygen desaturation or an arousal associated with that. Less than five is considered to be normal. Anything five or more gives them a diagnosis of obstructive sleep apnea, and then we stratify them based on the AHI. But it's important to take a look at more than just the apnea-hypopnea index. And while my eyes too on various reports like echocardiograms want to jump to the impression, it is important to take a look at that full report, see what their oxygen levels averaged and what they dipped down to. The arousal index, which is how many times a patient may have woken up briefly throughout the night. Take a look at the histogram, usually an image at the bottom of their report that shows what sleep fragmentation may have been like so that you can take that all in and make that decision. How important are these study findings, and is this a person that would benefit from treatment?  Dr Berkowitz: That's a fantastic overview of sleep studies and some of the highlights to look out for, even if we won't be understanding every detail as you would to know most importantly the caveats about home sleep testing having a fairly high percentage of false negative and false positive results. So being wary if our suspicion is high, and that test is normal or inconclusive to get an in-lab sleep study. And if our suspicion is low or maybe we haven't ordered the test and the patient has had it done elsewhere, and the history doesn't really match up to know that there are false positives on the home studies as well, and again, an in-lab study to settle the diagnosis. Is that right?  Dr Stahl: Yes.  Dr Berkowitz: Okay. Now, for most neurologists, probably if we diagnose OSA, we will be referring the patient to a sleep specialist like yourself for treatment. I think we're all familiar with CPAP and patients being on CPAP. Your article mentions a number of treatment modalities I admit I have not heard of before or maybe heard of in passing, acknowledging most general neurologists are not going to be prescribing or knowing with the nuance that you do as an expert how to decide which treatment a patient would most benefit from or most qualify for. So, can you just give us a broad overview, again, for the general neurologist acknowledging we might see a patient whose past medical history says OSA being treated with fill in the blank. What are the different treatment modalities, and how do you think, just so we can learn from you in broad brush strokes, about particular treatments for particular patients?  Dr Stahl: As you mentioned, most people are familiar with positive airway pressure or PAP therapy, and that does remain our most efficacious treatment. The way I explain it to patients is why PAP therapy is the most effective treatment is it's the only treatment that can take all of the tissues of that upper airway and open them up. Whereas all of our other treatments, we're going to target smaller spaces of that upper airway. So, our first option is if we can get somebody on PAP therapy, we know that that's going to be the best option for the majority. PAP therapy works by basically acting as an air splint to open up the air tissues. Know that masks are not interchangeable. There are masks that cover the nose and go over the nose and mouth and under the nose. Full face masks that cover the nose and mouth, they do typically require higher pressures, also tend to be less comfortable for a lot of patients as well. In addition to different PAP masks, there's different modalities of positive airway pressure therapy too. There are machines that auto-adjust, some that provide fixed pressure, bi-level PAP that provides a higher inspiratory pressure, lower expiratory pressure. Then outside of PAP therapy, there are, as you alluded to, a lot of options and more, continuing to come down the pipeline as well. Mandibular advancement devices or a form of oral appliances has been around for a while. This is device that somebody wears in their mouth. It's preferably customized for their teeth and titratable, meaning that they can make adjustments that pulls their mandible forward in relation to the maxilla in order to pull those tongue tissues further away from the back of the upper airway. That's ideally managed by a qualified sleep dentist or someone that specializes in oral appliance management. Other treatments include surgical options, including hypoglossal nerve stimulation, which is an implanted device that causes the tongue to protrude repetitively throughout their sleep period to hopefully open up the airspace. There's some other surgical options too that open up various places of the upper airway. There's a daytime treatment of obstructive sleep apnea, transoral neuromuscular electrical stimulation that changes the muscle fiber type of the tongue. And then there's some adjunctive treatments that can be helpful too, such as positional therapy, oral facial myofunctional therapy that helps a person breathe better through their nose and may help train the upper airway muscles.  Dr Berkowitz: Great. Well, that's a very helpful overview, and again, I refer our listeners to your article, which talks about all of those modalities in very comprehensive detail. So, Dr. Stahl, as we wrap up our conversation, you have a captive audience of neurologists and neurology trainees here. What would you like to leave us with that every neurologist should know about obstructive sleep apnea?  Dr Stahl: The most important, again, is for neurologists to know that obstructive sleep apnea is so common in your patient population, and it can have a significant negative impact on quality of life and health, including many neurologic conditions. And at the same time, obstructive sleep apnea is very treatable. We have so many options nowadays that we can usually get someone onto adequate treatment. And treatment has that potential to improve several neurologic symptoms and disorders, even at times when you don't think that there's an opportunity to improve symptoms such as say in, headache. So, neurologists really should be screening for signs and symptoms of obstructive sleep apnea, as well as considering testing in high-risk, potentially asymptomatic or minimally symptomatic patients.  Dr Berkowitz: That's a fantastic overview of some of the many pearls that you shared with us today, as well as in your article. So, thank you so much again. Today, I've been interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the August 2026 Continuum issue on neurology of sleep. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining today, and thank you again, Dr. Stahl.  Dr Stahl: Thank you again for having me.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.  

Dr. Jessica Ailani talks with Dr. Serena Orr about the genetic risk of migraine and post-traumatic headache in children.  Read the related article in Neurology®Genetics.  Disclosures can be found at Neurology.org. 

What if the biggest missing piece in chiropractic care isn't the spine... but is in the feet?In this episode of TechTalk Healthcare, Dr. Jay Greenstein and Brad Cost sit down with Dr. Andrew Powell, founder of Better Balance Orthotics, to explore how proprioceptive orthotics are helping chiropractors improve patient outcomes by stimulating the nervous system instead of simply supporting the foot.Dr. Powell explains the science behind the foot-brain connection, why traditional orthotics often fail to create lasting change, and how neurological input from the feet influences posture, balance, movement, scoliosis, chronic pain, and overall function.You'll learn:Why supportive orthotics may not solve the root cause of dysfunctionThe difference between support-based and proprioceptive orthoticsHow sensory input from the feet impacts the brain and nervous systemThe role of foot mechanics in posture, balance, scoliosis, and spinal healthHow chiropractors can incorporate neurological orthotics into their practicesThe business model behind offering Better Balance Orthotics to patientsWhether you're a chiropractor, healthcare provider, or someone interested in improving movement and balance, this episode offers a fresh perspective on how optimizing foot function can transform whole-body health.Topics Covered: Chiropractic, Orthotics, Proprioception, Foot Health, Balance, Posture, Neurology, Functional Movement, Scoliosis, Chiropractic Technology, Practice Growth, Better Balance Orthotics

Alpha-lipoic acid (ALA) is a naturally occurring fatty acid. It has several plausible mechanisms for slowing ALS progression. Preclinical studies showed ALA slowed motor function decline. Some patients reported improvement when taking ALA together with other supplements. Here we discuss the mechanism, clinical studies, and potential risks. 

Dr. Paul Crane talks with Drs. Fiifi Duodu and Malya Sahu about neuroimmunology and multiple sclerosis diagnosis in Africa, including challenges and efforts to improve care.  Read the related article here.  Disclosures can be found at Neurology.org.   

Dr. Elizabeth Coon and Dr. Lucy Norcliffe-Kaufmann discuss the mechanism-based therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, highlighting recent clinical trial results and future directions.  Show citation:  Freeman R, Kaufmann H, Biaggioni I, et al. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial. Neurology. 2026;107(3):e218284. doi:10.1212/WNL.0000000000218284 

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about a pilot American Board of Psychiatry and Neurology Academic Pathway, a study of the EpiWatch app, and a new approach to magnetic resonance scanning.

In part two of this series, Dr. Halley Alexander and Dr. Heidi Munger Clary discuss the steps to take if you are screening for a psychiatric comorbidity and the results indicate that someone may be positive for depression, anxiety, or another condition.  Show citations:  Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63(2):316-334. doi:10.1111/epi.17140  Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update. Neurology. 2018;91(18):829-836. doi:10.1212/WNL.0000000000006425  

Dr. Elizabeth Coon talks with Dr. Lucy Norcliffe-Kaufmann about the mechanism-based therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, highlighting recent clinical trial results and future directions.  Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

If you enjoy this episode, we're sure you will enjoy more content like this on The Occult Rejects.  In fact, we have curated playlists on occult topics like grimoires, esoteric concepts and phenomena, occult history, analyzing true crime and cults with an occult lens, Para politics, and occultism in music. Whether you enjoy consuming your content visually or via audio, we've got you covered - and it will always be provided free of charge.  So, if you enjoy what we do and want to support our work of providing accessible, free content on various platforms, please consider making a donation to the links provided below.  Thank you and enjoy the episode!Links For The Occult Rejectshttps://linktr.ee/theoccultrejectsOccult Research Institutehttps://www.occultresearchinstitute.org/Substackhttps://substack.com/@theoccultrejects?r=7auau0&utm_campaign=profile&utm_medium=profile-pageCash Apphttps://cash.app/$theoccultrejectsVenmo@TheOccultRejectsBuy Me A Coffeebuymeacoffee.com/TheOccultRejectsPatreonhttps://www.patreon.com/TheOccultRejectsBibliographyCore Eye Anatomy, Retina, Optic Nerve, and Visual PathwaysBelliveau, A. P., & Somani, A. N. “Pupillary Light Reflex.” StatPearls. Treasure Island, FL: StatPearls Publishing, updated 2023.Cleveland Clinic. “Optic Nerve: What It Is, Function, Anatomy & Conditions.” Cleveland Clinic, updated 2024.Gupta, M., & Ireland, A. C. “Neuroanatomy, Visual Pathway.” StatPearls. Treasure Island, FL: StatPearls Publishing, updated 2022.Kolb, H. “Simple Anatomy of the Retina.” Webvision: The Organization of the Retina and Visual System. University of Utah / NCBI Bookshelf.Purves, D., Augustine, G. J., Fitzpatrick, D., et al., eds. Neuroscience. Sunderland, MA: Sinauer Associates.Szabadi, E. “Functional Organization of the Sympathetic Pathways Controlling the Pupil: Light-Inhibited and Light-Stimulated Pathways.” Frontiers in Neurology 9, 2018.University of Texas Health Science Center at Houston. “Ocular Motor System.” Neuroscience Online.Pupillometry, Cognitive Load, Attention, and Mental EffortBeatty, Jackson. “Task-Evoked Pupillary Responses, Processing Load, and the Structure of Processing Resources.” Psychological Bulletin 91, no. 2, 1982: 276–292.Beatty, Jackson, and Brennis Lucero-Wagoner. “The Pupillary System.” In Handbook of Psychophysiology, edited by John T. Cacioppo, Louis G. Tassinary, and Gary G. Berntson. Cambridge: Cambridge University Press, 2000.Kahneman, Daniel, and Jackson Beatty. “Pupil Diameter and Load on Memory.” Science 154, no. 3756, 1966: 1583–1585.Kahneman, Daniel. Attention and Effort. Englewood Cliffs, NJ: Prentice-Hall, 1973.Laeng, Bruno, Sylvain Sirois, and Gustaf Gredebäck. “Pupillometry: A Window to the Preconscious?” Perspectives on Psychological Science 7, no. 1, 2012: 18–27.Mathôt, Sebastiaan. “Pupillometry: Psychology, Physiology, and Function.” Journal of Cognition 1, no. 1, 2018.Piquado, Tepring, David Isaacowitz, and Arthur Wingfield. “Pupillometry as a Measure of Cognitive Effort in Younger and Older Adults.” Psychophysiology 47, no. 3, 2010: 560–569.Zekveld, Adriana A., Sophia E. Kramer, and Tammo Houtgast. “The Pupil Dilation Response to Auditory Stimuli: Current State of Knowledge.” Trends in Hearing 22, 2018.Emotion, Attraction, Arousal, and the PupilBradley, Margaret M., Laura Miccoli, Miguel A. Escrig, and Peter J. Lang. “The Pupil as a Measure of Emotional Arousal and Autonomic Activation.” Psychophysiology 45, no. 4, 2008: 602–607.de Winter, Joost C. F., et al. “Replicating Five Pupillometry Studies of Eckhard Hess.” International Journal of Psychophysiology 165, 2021: 145–161.Hess, Eckhard H. “Attitude and Pupil Size.” Scientific American 212, no. 4, 1965: 46–54.Hess, Eckhard H., and James M. Polt. “Pupil Size as Related to Interest Value of Visual Stimuli.” Science 132, no. 3423, 1960: 349–350.Lang, Peter J., Margaret M. Bradley, and Bruce N. Cuthbert. International Affective Picture System (IAPS): Affective Ratings of Pictures and Instruction Manual. Gainesville: University of Florida, 2008.Pan, J., et al. “The Effects of Emotional Arousal on Pupil Size Depend on Background Luminance and Stimulus Type.” Scientific Reports 14, 2024.Locus Coeruleus, Norepinephrine, Salience, and AttentionAston-Jones, Gary, and Jonathan D. Cohen. “An Integrative Theory of Locus Coeruleus–Norepinephrine Function: Adaptive Gain and Optimal Performance.” Annual Review of Neuroscience 28, 2005: 403–450.Joshi, Siddhartha, Yin Li, Ram M. Kalwani, and Joshua I. Gold. “Relationships Between Pupil Diameter and Neuronal Activity in the Locus Coeruleus, Colliculi, and Cingulate Cortex.” Neuron 89, no. 1, 2016: 221–234.Murphy, Peter R., Ian H. Robertson, James H. Balsters, and Redmond G. O'Connell. “Pupillometry and P3 Index the Locus Coeruleus–Noradrenergic Arousal Function in Humans.” Psychophysiology 48, no. 11, 2011: 1532–1543.Sara, Susan J. “The Locus Coeruleus and Noradrenergic Modulation of Cognition.” Nature Reviews Neuroscience 10, 2009: 211–223.Uddin, Lucina Q. “Salience Processing and Insular Cortical Function and Dysfunction.” Nature Reviews Neuroscience 16, 2015: 55–61.Memory, Emotion, Initiation, and Ritual EncodingCahill, Larry, and James L. McGaugh. “Mechanisms of Emotional Arousal and Lasting Declarative Memory.” Trends in Neurosciences 21, no. 7, 1998: 294–299.McGaugh, James L. “Memory—A Century of Consolidation.” Science 287, no. 5451, 2000: 248–251.McGaugh, James L. “The Amygdala Modulates the Consolidation of Memories of Emotionally Arousing Experiences.” Annual Review of Neuroscience 27, 2004: 1–28.Seligman, Rebecca, and Laurence J. Kirmayer. “Dissociative Experience and Cultural Neuroscience: Narrative, Metaphor and Mechanism.” Culture, Medicine, and Psychiatry 32, 2008: 31–64.Seligman, Rebecca, Ryan A. Brown, and Laurence J. Kirmayer. “Theory and Method at the Intersection of Anthropology and Cultural Neuroscience.” Social Cognitive and Affective Neuroscience 5, no. 2–3, 2010: 130–139.Whitehouse, Harvey. Arguments and Icons: Divergent Modes of Religiosity. Oxford: Oxford University Press, 2000.Whitehouse, Harvey. Modes of Religiosity: A Cognitive Theory of Religious Transmission. Walnut Creek, CA: AltaMira Press, 2004.Ritual, Synchrony, Social Bonding, and Embodied MeaningHobson, Nicholas M., Juliana Schroeder, Jane L. Risen, Dimitris Xygalatas, and Michael I. Norton. “The Psychology of Rituals: An Integrative Review and Process-Based Framework.” Personality and Social Psychology Review 22, no. 3, 2018: 260–284.Jackson, Joshua Conrad, Brock Bastian, and others. “Synchrony and Physiological Arousal Increase Cohesion and Cooperation in Large Naturalistic Groups.” Scientific Reports 8, 2018.McCauley, Robert N., and E. Thomas Lawson. Bringing Ritual to Mind: Psychological Foundations of Cultural Forms. Cambridge: Cambridge University Press, 2002.Rappaport, Roy A. Ritual and Religion in the Making of Humanity. Cambridge: Cambridge University Press, 1999.Turner, Victor. The Ritual Process: Structure and Anti-Structure. Chicago: Aldine, 1969.Xygalatas, Dimitris. Ritual: How Seemingly Senseless Acts Make Life Worth Living. New York: Little, Brown Spark, 2022.Xygalatas, Dimitris, et al. “Extreme Rituals Promote Prosociality.” Psychological Science 24, no. 8, 2013: 1602–1605.Meditation, Prayer, Trance, and AbsorptionFox, Kieran C. R., Matthew L. Dixon, Savannah Nijeboer, et al. “Functional Neuroanatomy of Meditation: A Review and Meta-Analysis of 78 Functional Neuroimaging Investigations.” Neuroscience & Biobehavioral Reviews 65, 2016: 208–228.Jerath, Ravinder, John W. Crawford, Vernon A. Barnes, and Kyler Harden. “Self-Regulation of Breathing as a Primary Treatment for Anxiety.” Applied Psychophysiology and Biofeedback 40, 2015: 107–115.Lutz, Antoine, John D. Dunne, and Richard J. Davidson. “Meditation and the Neuroscience of Consciousness.” In The Cambridge Handbook of Consciousness, edited by Philip David Zelazo, Morris Moscovitch, and Evan Thompson. Cambridge: Cambridge University Press, 2007.Tellegen, Auke, and Gilbert Atkinson. “Openness to Absorbing and Self-Altering Experiences (‘Absorption'), a Trait Related to Hypnotic Susceptibility.” Journal of Abnormal Psychology 83, no. 3, 1974: 268–277.Vago, David R., and David A. Silbersweig. “Self-Awareness, Self-Regulation, and Self-Transcendence: A Framework for Understanding the Neurobiological Mechanisms of Mindfulness.” Frontiers in Human Neuroscience 6, 2012.Darkness, Sensory Deprivation, Ganzfeld, and Visual InstabilityCaputo, Giovanni B. “Strange-Face-in-the-Mirror Illusion.” Perception 39, no. 7, 2010: 1007–1008.Caputo, Giovanni B. “Visual Perception During Mirror-Gazing at One's Own Face in Patients with Depression.” The Scientific World Journal, 2014.Caputo, Giovanni B. “Strange-Face Illusions During Eye-to-Eye Gazing in Dyads.” Imagination, Cognition and Personality 38, no. 1, 2018: 51–77.Metzger, Wolfgang. “Optische Untersuchungen am Ganzfeld.” Psychologische Forschung 13, 1930: 6–29.Shenyan, O., et al. “Visual Hallucinations Induced by Ganzflicker and Ganzfeld Differ in Frequency, Complexity, and Content.” Scientific Reports 14, 2024.Wackermann, Jiří, Peter Pütz, and Carsten Allefeld. “Ganzfeld-Induced Hallucinatory Experience, Its Phenomenology and Cerebral Electrophysiology.” Cortex 44, no. 10, 2008: 1364–1378.Zuckerman, Marvin, and Nathan Cohen. “Sources of Reports of Visual and Auditory Sensations in Perceptual-Isolation Experiments.” Psychological Bulletin 61, no. 1, 19Also want to remind people about the website, if you're into reading we have tons of information by multiple contributors, and we got t-shirts up on the site if you're interested. Fun fact, the art is all based on the eyeball. 

We get more listener emails about diet and MS than almost any other topic. If you're curious about how some of the well-known diets for MS actually stack up, or you're interested in understanding the connection between diet and MS-related fatigue, or you want to know what the biggest obstacle to staying on a new diet is (and this may surprise you), then this is the episode for you. We're devoting this week's entire episode to my conversation with Dr. Tyler Titcomb, an assistant professor in the Department of Dietetics and Nutrition, and a registered dietitian with a PhD in Nutritional Sciences in the Department of Neurology at the University of Kansas Medical Center. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: We're taking a deep dive into diet and MS  :22 Dr. Tyler Titcomb breaks down what you need to know about how diet influences multiple sclerosis and why it plays such a key role.  :54 Share this episode  25:22 Next week  25:41 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/466 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 466 Guest: Dr. Tyler Titcomb Privacy Policy

The August 2026 recall showcases five incredible interviews highlighting recent advances in headache medicine. The episode begins with Dr. Patricia Pozo-Rosich discussing the latest advancements in headache medicine, focusing on key research findings from 2025. The episode continues with Dr. Jennifer Robblee discussing the latest consensus on refractory migraine. In the third episode of this series, Dr. Michael Eller discusses the implications of CGRP therapies in migraine treatment.  The recall concludes with a two-part discussion featuring Drs. Tesha Monteith and Peter Goadsby, who highlight major developments in headache medicine presented at the 2026 AAN Annual Meeting.   Podcast links:    The Best of Headache Medicine from 2025: A Year in Review   Refractory Headache Disorders, New Consensus, and Emergency Department Migraine Guidelines   CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke   Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 1  Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 2  Article links:  Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke   Disclosures can be found at Neurology.org. 

While the Spanish flu was tearing across the globe,another epidemic began stealing people's bodies from them.Encephalitis lethargica aka “sleepy sickness” - could make victimssleep almost continuously. It could also cause insomnia,hallucinations, involuntary movements, dramatic personality changes,paralysis, and death. Those who survived sometimes became livingstatues, unable to initiate even the smallest movement as lifecontinued around them.Chris and Ed trace this forgotten plague from World War I Europe tothe institutions where survivors remained trapped for decades.SHOW NOTESOriginally aired on Patreon: 09/25/25https://satt.short.gy/nfu16 Originally aired on Patreon: 09/18/25 Want even more out of SATT? Now you can SUPPORT THE SHOW and get NEW SATT content EVERY WEEK for as little as 5 BONES — which includes our bonus video show New Fear Unlocked — by joining CLUB SATT: www.patreon.com/scaredallthetimeBecome a supporter of this podcast: https://www.spreaker.com/podcast/scared-all-the-time--7084296/support.Get the latest episodes of our bonus show NEW FEAR UNLOCKED -- and a whole lot more! -- by supporting the show on Patreon: https://www.patreon.com/ScaredAllTheTime

In part two of this series, Dr. Shuvro Roy talks with Drs. Jiwon Oh and Amit Bar-Or about the latest developments in BTK inhibitors for MS, including safety signals, trial results, and future directions.  For more information, please read about the abstract that was presented at the 2026 AAN Annual Meeting.  Read more about the Fenebrutinib Trial.  Disclosures can be found at Neurology.org. 

*Content Warning:  neglect, rejection, friendship betrayal, betrayal, and infidelity.Free + Confidential Resources + Safety Tips: somethingwaswrong.com/resources   SWW Sticker Shop!: https://brokencyclemedia.com/sticker-shop SWW S26 Theme Song & Artwork: The S26 cover art is by the Amazing Sara Stewart instagram.com/okaynotgreat/  Follow Something Was Wrong: Website: somethingwaswrong.com  IG: instagram.com/somethingwaswrongpodcast TikTok: tiktok.com/@somethingwaswrongpodcast  Follow Tiffany Reese: Website: tiffanyreese.me  IG: instagram.com/lookieboo Follow Dr. Marisa G. Franco: Website - https://www.drmarisagfranco.com/ Instagram - https://www.instagram.com/drmarisagfranco Platonic, How The Science of Attachment Can Help You Make - and Keep - Friends - https://drmarisagfranco.com/platonic-the-book/ Worth, The New Science of Self-Esteem and Secure Attachment: https://drmarisagfranco.com/worth-the-book/ *Sources:  Almaatouq, Abdullah, et al. "Are You Your Friends' Friend? Poor Perception of Friendship Ties Limits the Ability to Promote Behavioral Change." PLOS ONE, vol. 11, no. 3, 2016, article e0151588, https://doi.org/10.1371/journal.pone.0151588 Center for the Study of Traumatic Stress. When Losses of Loved Ones Are Not Acknowledged: Understanding Disenfranchised Grief. Department of Psychiatry, Uniformed Services University, n.d., https://www.cstsonline.org/assets/media/documents/CSTS_FS_When_Losses_of_Loved_Ones_Are_Not_Acknowledged_Understanding_Disenfranchised_Grief.pdf Dodson, William W., et al. "Rejection sensitivity dysphoria in attention-deficit/hyperactivity disorder: A case series." Neurology 7 (2024): 23-30.  Franco, Marisa G. Platonic: How the Science of Attachment Can Help You Make—and Keep—Friends. Penguin Random House, 6 Sept. 2022 https://www.penguinrandomhouse.com/books/676695/platonic-by-marisa-g-franco-phd/ Franco, Marisa G. Worth: The New Science of Self-Esteem and Secure Attachment. G.P. Putnam's Sons, 15 Sept. 2026, Penguin Random House,https://www.penguinrandomhouse.com/books/784327/worth-by-marisa-g-franco-phd/ Gobin, Robyn L., and Jennifer J. Freyd. "The impact of betrayal trauma on the tendency to trust." Psychological Trauma: Theory, Research, Practice, and Policy 6.5 (2014): 505. https://psycnet.apa.org/record/2013-24397-001 Guy-Evans, Olivia. “Self-Verification Theory.” Simply Psychology, 11 May 2026, https://www.simplypsychology.org/self-verification-theory.html Here & Now Newsroom. “Research Shows We Replace Half Our Friends Every 7 Years. Here's How to Make New Ones.” NPR Illinois, 23 June 2025, https://www.nprillinois.org/2025-06-23/research-shows-we-replace-half-our-friends-every-7-years-heres-how-to-make-new-ones Hillman, James. "Betrayal." Loose Ends: Primary Papers in Archetypal Psychology, Spring Publications, 1975, pp. 63–79. Jarrett, Christian. "The Liking Gap: We Usually Think People Like Us Less Than They Actually Do." Research Digest, British Psychological Society, 13 Sept. 2018, https://www.bps.org.uk/research-digest/liking-gap Kenny, Serafina. "Having Friends Is as Important as Diet and Exercise for Living Longer, a Longevity Expert Says." Business Insider, 22 Sept. 2023, https://www.businessinsider.com/longevity-antiaging-friendship-social-interaction-relationships-2023-9 Nader, Karim. “Reconsolidation and the Dynamic Nature of Memory.” Cold Spring Harbor perspectives in biology vol. 7,10 a021782. 9 Sep. 2015, doi:10.1101/cshperspect.a021782, https://pubmed.ncbi.nlm.nih.gov/26354895/ Nussbaum, Ben. "FRIENDSHIP FLATTENS HILLS: It's time to put connections at the center of wellbeing, says relationship expert Marisa Franco." Spirituality & Health Magazine, vol. 25, no. 5, Sept.-Oct. 2022, pp. 46+. Gale Academic OneFile link.gale.com/apps/doc/A763799199/AONE?u=anon~858b38f4&sid=googleScholar&xid=6b08179d One Another. Directed by Amber Love, produced by Andrea Raby, Joycie Films, 2026. World premiere, SXSW Film & TV Festival, Austin, TX, 12 Mar. 2026. https://schedule.sxsw.com/2026/films/2249924 Romm, Cari. "Half of Your Friends Probably Don't Think of You as a Friend." The Cut, 9 May 2016, https://www.thecut.com/2016/05/half-of-your-friends-probably-dont-think-of-you-as-a-friend.html Thompson, Sophia, Kaitlyn Deaner, and Marisa G. Franco. "How to Help Clients Make Friends." Journal of Health Service Psychology 49.2 (2023): 77-85 https://link.springer.com/article/10.1007/s42843-023-00085-w Wallace, Anna Kodé. "Why Friendship Betrayal Feels Impossible to Get Over." The Cut, 22 Apr. 2026, https://www.thecut.com/article/friendship-betrayal-explained-psychology-summer-house.html